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ABSTRACT 
 Robust cell-mediated immune responses are considered vital for successful 
vaccination against intracellular pathogens and cancer. Enhancing antigen uptake by 
dendritic cells (DCs) is a proposed way to stimulate cell-mediated immune responses 
when using typically low immunogenic protein antigens. Formulating antigen into a 
nanoparticle carrier can increase antigen uptake by two major antigen-presenting cells 
(APCs), DCs and macrophages. However, macrophage uptake is generally accepted as 
the main route of nanoparticle clearance due to macrophages’ high phagocytic 
capability. To skew the antigen uptake by DC, previous approaches have relied on 
attaching complex targeting moieties to antigen itself or onto nanoparticle antigen 
carriers such as liposomes. We hypothesized that by retarding high macrophage uptake 
of liposomes, we could facilitate enhanced uptake of liposomes by DCs. Simple 
liposome formulations containing phosphatidylinositol (PI) or 
monosialotetrahexosylganglioside (GM1) are well documented to deter rapid uptake by 
macrophages. In vitro uptake studies showed that incorporating 10mol% PI promoted 
uptake by DCs, while having minimal effect on uptake by macrophages. This trend was 
not observed with 10mol% GM1 incorporation. In vivo uptake studies upon 
subcutaneous injection confirmed PI-liposomes are indeed internalized more by DCs 
than GM1-liposomes, however, this result was also observed in macrophages. These 
liposomal formulations are of interest as vaccine carriers to stimulate enhanced cell-
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mediated immune responses and the generation of CD8+ T cells via enhanced uptake 
by DCs.  Extending on our previous work using liposomes co-encapsulating the model 
antigen (OVA) and a hemolysin, listeriolysin-O (LLO), we show, herein, that PI- and 
GM1-liposomes encapsulating OVA and LLO can deliver OVA to the cytosol of DCs and 
macrophages in cell culture, resulting in efficient antigen presentation to CD8+ T cells. 
Mice immunized with PI-liposomes or GM1-liposomes co-encapsulating OVA and LLO 
generated similar CD8+ T cell-mediated immune responses as determined by MHC I 
tetramer staining and IFN−gamma ELISPOT analysis. Vaccination with either liposome 
formulation resulted in enhanced antigen-specific serum IgG2a titers indicative of better 
Th1 helper T cell activation. Both PI-liposomes and GM1-liposomes represent simple, 
inexpensive vaccine carriers for effectively stimulating cell-mediated immune responses 
utilizing subunit protein antigens.  	
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CHAPTER 1 
Directing Vaccine Delivery to Dendritic Cells 
 
INTRODUCTION 
Vaccination approaches in history 
One of the most important medical discoveries, the act of vaccination, remains 
the most powerful and cost-effective tool for preventing disease [1]. As a result of 
widespread vaccination, the incidence and mortality of life-threatening diseases such a 
diphtheria, meningitis, measles, polio, and smallpox has been reduced by >97-99% [2, 
3]. Most vaccines in use today consist of live attenuated pathogen, inactivated 
pathogen, or protein subunit preparations. Live attenuated pathogens are the most 
successful vaccines and have been administered to billions of people worldwide, 
conferring protective immunity that often lasts for decades with just one vaccination [1, 
4]. Live attenuated vaccines are effective at preventing infection because the vaccine 
elicits strong cellular and antibody immune responses, mimicking the protective 
immunity a person would develop in response to a natural infection [4]. However, the 
use of live attenuated vaccines is limited to invariant pathogens and infections that can 
be reduced as a result of prior exposure(s). Even live attenuated vaccines would not be 
effective at controlling some of the world’s most concerning diseases resulting from the 
variable pathogen human immunodeficiency virus (HIV), or malaria, where prior
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infections do not confer lasting immunity [1]. Furthermore, live vaccination is 
contraindicated for immunocompromised individuals, which includes patients with 
HIV/AIDS, young children, and the elderly population. Safety issues are also of concern 
considering that live attenuated pathogens persistently replicate inside the host, leaving 
the potential to revert back to a pathogen with partial or full virulence, as was the case 
with the oral polio vaccine [5]. Safety concerns stemming from live vaccination together 
with increased knowledge on recombinant expression of proteins shifted vaccine 
development towards protein subunit vaccine preparations [3, 4]. Subunit protein 
vaccines utilize antigenic protein(s) to initiate host immune responses. The drawback of 
this type of vaccine is that poorly immunogenic protein antigen(s) are primarily 
responsible for conferring immunity in a host.  The success of protein subunit vaccines 
has so far been limited as many fail to produce protective, memory immune responses 
[1, 6]. 
 
Intracellular pathogens require cellular immune responses 
All currently licensed vaccines (killed or inactivated, whole-cell, recombinant 
protein, or live attenuated) generate humoral [antibody] immune responses (Table 1.1) 
[7-9]. Antibody production as a result of vaccination is effective against many viral and 
bacterial infections [3, 10]. However, for intracellular viral infections or cancer-causing 
cells, antibody production alone is not the proper immune response to clear the infection 
or disease. Many intracellular pathogens such as HIV, Plasmodium (causing malaria), 
hepatitis C, and Mycobacterium tuberculosis, which require cell-mediated immune 
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responses in addition to humoral responses in order to protect the host, remain without 
effective vaccines [1, 10-13]. Cell-mediated immune responses involve eliminating 
infected or cancerous cells via the cytotoxic T lymphocytes (CTLs) with support from T 
helper (Th) 1 cells. This type of response is primarily directed at intracellular pathogens, 
which persist inside host cells protected from antibody recognition and opsonization.  
Many of the marketed live attenuated vaccines including those against hepatitis A, 
hepatitis B, influenza, varicella, typhoid fever and measles have been shown to induce 
cell-mediated immune responses (Table 1.1). Those cellular immune responses 
generated are believed to be in part responsible for the long-lasting protective immunity 
generated against these pathogens [9]. However, as mentioned previously, safety 
concerns of live vaccines have limited their future development. New vaccine strategies 
focus on enhancing the immunogenicity of protein subunit vaccines. To increase the 
effectiveness of protein subunit vaccines often requires the use of high antigen doses, 
booster immunizations, the addition of an adjuvant(s), or a combination of these 
measures [9]. 
 
Types of adjuvants 
Adjuvants are a heterogenous group of substances that are capable of increasing 
or modulating humoral and/or cellular immune responses to the delivered antigen [14]. 
When utilized in vaccine formulations, adjuvants can facilitate a decrease in antigen 
amounts required in the formulation, less frequent vaccine dosing, improved responses 
among former non-responders, and stronger, swifter immune responses [15]. Adjuvants 
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can be broadly separated into two main classes, immunostimulants and delivery 
systems. Adjuvants found in either class can be used as the only adjuvant component in 
vaccine formulations but a combination of immunostimulant and a delivery system has 
been shown to further enhance immune responses and even provide a synergistic effect 
[16].  
Immunostimulants  
Adjuvants classified as immunostimulants activate the innate immune response. 
Many of these adjuvants are pathogen-associated molecular patterns (PAMPs), 
conserved components of microbes (e.g. viral nucleic acids, components of bacterial 
and fungal cell walls and flagellar protein) that are not found in eukaryotic life. Receptors 
that recognize these PAMPs, called pattern recognition receptors (PRRs), provide the 
innate immune system with a way to distinguish self and non-self derived molecules 
[17]. There are many receptor families defined as PRRs, including toll-like receptors 
(TLRs), C-type lectin receptors (CLRs) and RIG-I-like receptors (RLRs). 
Delivery systems 
This first generation of adjuvants includes the aluminum salts (collectively termed 
as alum), oil-in-water emulsions, polymeric particles and liposomes. Alum and 
emulsions induce local inflammation which recruits immune cells to the site of injection 
resulting in increased antigen exposure [18]. Polymeric particles and liposomes act as 
adjuvants by protecting the antigen against degradation and enhancing antigen delivery 
to antigen-presenting cells of the immune system [17]. Both approaches extend antigen 
duration in the host and additionally increase uptake of the antigen by immune cells, 
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providing an adjuvant effect. 
 
Immune system responses 
The immune system is comprised of two response types, the innate and the 
adaptive. The innate immune response is an immediate, non-pathogen specific 
response to infection. Using a variety of PRRs the innate immune system can sense self 
from non-self by PAMPs [19]. PAMPs are conserved patterns commonly expressed by 
microbes including viral nucleic acids, components of bacterial and fungal cell walls and 
flagellar proteins [20]. Innate immune responses are essential for early inhibition of 
infection and viral/bacterial proliferation. The innate immune system functions to 
produce molecules that stimulate the immune system (e.g., chemokines, cytokines and 
interferons (IFNs)) and activate leukocytes (e.g., macrophages) in response to infection 
[21].  
The other branch of the immune system, the adaptive immune response, takes 
anywhere from days to weeks to develop and is an antigen-specific response to 
infection. The adaptive immune response relies on the innate immune response to 
recognize whether a detected antigen is self or non-self. Based on the determination of 
non-self, the adaptive immune response develops to aid in long-term protective 
immunity towards the antigen [19]. Memory cells are activated by the adaptive immune 
response to provide an immunological memory of encountered pathogens. Upon future 
encounters with a memorized pathogen, the immune system is able to react faster and 
stronger to clear the infection [22].  
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Tailoring adaptive immune responses 
The adaptive immune response is further divided into the cell-mediated and 
humoral responses. While the cell-mediated immune response is essential for directly 
killing infected cells, the antibody response provided by humoral immunity is important 
for lasting protective immunity [23]. The branch of adaptive immunity that is activated is 
dependent on where the antigen is detected in the cell. The major histocompatibility 
complex (MHC) class I and class II pathways deliver antigen found inside the cell to the 
cell surface for immune recognition. The purpose of the MHC class I pathway is to 
present antigens found in the cytosol while MHC class II molecules present antigens 
found in the endocytic pathway [24]. The MHC molecules that perform the actions of 
binding and presenting antigen have distinct immune activating properties. MHC class I 
molecules brought to the surface with an exogenous antigen activate CD8+ T cells 
(CTLS). Activation of CTLs promotes the specific lysis of infected cells necessary for 
clearing intracellular infections. MHC class II molecules brought to the surface with 
exogenous antigen recognized in the endocytic pathway will activate CD4+ T cells [24, 
25].  
CD4+ T cells can polarize into Th1 or Th2 cells that can either enhance or inhibit 
cell-mediated immunity, respectively [26]. Skewing towards Th1 promotes cell 
mediated-immunity with the secretion of Th1-type cytokines such as IL-12, TNF-α and 
IFN-γ. These molecules enhance the activation of CTLs and macrophages and promote 
the differentiation of B cells [23, 26]. B cells that are activated by Th1-type cytokines 
secrete IgG2a, an opsonizing antibody associated with viral clearance. On the other 
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hand, skewing T cell differentiation towards Th2 results in IL-4 and IL-5 production and 
the proliferation of B cells that secrete IgG1, a neutralizing antibody [26-28]. A Th2 type 
response promotes the other side of adaptive immunity, the humoral response [23]. All 
currently approved vaccines evoke humoral immune responses. However, humoral 
immunity alone is not able to clear some intracellular infections. Additional components 
are needed to skew Th1 polarization in response to vaccination [11].  
 
Antigen-presenting cells 
 Antigen-presenting cells (APCs) are defined by their expression of MHC class II 
molecules. Propagation of the immune response is dependent upon the ability of APCs 
to capture, internalize, process and present antigen on the cell surface via MHC 
molecules (I or II). Many cell types express MHC class II molecules including endothelial 
cells, epithelial cells, tumor cells, B lymphocytes, macrophages and dendritic cells 
(DCs). All cell types expressing MHC class II molecules are able to engage T cells in an 
antigen-specific manner. However, antigen-presenting cells have different efficiencies of 
antigen-presentation, leading to the term ‘professional’ APCs, which includes B cells, 
macrophages and DCs [29]. 
B lymphocytes 
 A B cell’s primary function is to produce antibodies. B cells are not particularly 
efficient in antigen capture due to poor phagocytic capability [30, 31]. Rather they are 
able to internalize antigen that binds via their immunoglobulin (Ig) surface receptors [32, 
33]. B cells express high levels of MHC class II molecules as well as abundant 
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costimulatory and adhesion molecules needed for T cell interactions. They are efficient 
at generating antigen-MHC complexes and MHC class II presentation to T cells, which 
in turn promotes B cell expansion and antibody production [29, 34]. 
Macrophages 
 Macrophages have an extraordinary capacity for internalizing antigen of many 
forms including soluble, whole-cell, and receptor- or ligand-bound [29, 35]. 
Macrophages express MHC-I and MHC-II as well as the costimulatory molecules 
needed for cell-cell interactions. However, their expression of MHC-II molecules is lower 
than that of B cells and DCs, which leads to a lower capacity to stimulate T cells [36, 
37]. In addition, the endocytic pathway of macrophages is more tailored for degradation 
than loading of antigen for subsequent MHC presentation to T cells [38, 39].   
Dendritic cells 
 Dendritic cells’ main function appears to be antigen-presentation to T cells [39]. 
DCs have a higher capacity to stimulate T cell interactions due to their high expression 
of MHC-II and costimulatory molecules [24, 29, 40, 41]. Lysosomes of immature DCs 
sequester large amounts of MHC-II molecules which antigen is ultimately directed to 
after internalization; however, only upon DC maturation can antigen-MHC complexes be 
efficiently presented to T cells. In response, DCs sequester antigen-MHC complexes in 
lysosomes until the immature DC has matured [42]. Thereafter, DCs have a unique 
ability to facilitate the movement of MHC II molecules from lysosomes to the cell surface 
[43, 44]. Further supporting their role in antigen-presentation, DC’s characteristic shape 
enables them to interact with multiple T cells simultaneously [29]. Due to these unique 
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properties, DCs’ ability to stimulate T cells can surpass macrophages’ by orders of 
magnitude [45, 46].  
 
Dendritic cell identification and plasticity 
 Ralph Steinman first identified dendritic cells in the peripheral lymphoid organs of 
mice in 1973. These cells were weakly and transiently adherent while displaying a 
distinctly different morphology from that of macrophages or lymphocytes. Dendritic cells 
are so named because of their stellate appearance, displaying dendrites from the body 
of the cell outwards [47]. Since initial discovery, research efforts on dendritic cells has 
grown expansively and several subsets of DCs have been identified, all of which have 
specialized functions in immune responses (Figure 1.1).  
The maturity of a given dendritic cell shapes that cell’s function.  Normally, DCs 
in the peripheral tissues and spleen, as well as approximately 50% of DC in the lymph 
nodes are immature [48, 49]. Immature dendritic cells (iDCs) are highly efficient at 
antigen capture and therefore act as early-warning systems for the presence of non-self 
antigens via numerous uptake routes such as phagocytosis, macropinocytosis and 
receptor-mediated endocytosis [25]. Macropinocytosis and receptor-mediated 
endocytosis, in particular, facilitate efficient antigen uptake. Antigen internalization by 
iDCs via these routes allow for antigen presentation even at nanomolar antigen 
concentrations, a distinct improvement from the usual micromolar values required by 
other APCs [24]. Antigen-capture and proper inflammatory maturation stimuli direct 
iDCs to mature. However, if DCs do not receive maturation signals (present in an 
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inflammatory environment), these cells will remain immature and antigen presentation 
will lead to immune regulation and/or suppression. Maturation of DCs is associated with 
the down-regulation of antigen-capture activity, the increased expression of surface 
MHC class II molecules and co-stimulatory molecules (CD86, CD80 and CD40), the 
ability to secrete cytokines, as well as the acquisition of CCR7, which allows migration 
of the DC into the draining lymph node. Mature DCs (mDCs) can initiate differentiation 
of antigen-specific T cells into effector T cells with unique functions and cytokine profiles 
and also interact with B cells for humoral responses [24, 49, 50]. 
 
The dendritic cell’s unique role in immunity 
From a vaccination standpoint, dendritic cells represent an important target for 
stimulating robust cellular immune responses towards delivered antigens. DCs are 
present in nearly all tissues with enriched cell numbers where antigen exposure is more 
frequent, such as in lymphoid organs, at body surfaces and at mucosal surfaces [51]. 
DCs are potent stimulators of T cells where in vitro it has been estimated that one mDC 
can activate 100-3,000 T cells, underlining their integral role in the development of cell-
mediated immune responses [24]. 
Antigen cross-presentation 
While both macrophages and dendritic cells are capable of the traditional MHC 
Class I and II types of antigen presentation, it is DCs that are unique in their ability to 
“cross-present” antigens to T cells and induce T cell activation in vivo [43, 52, 53]. 
Cross-presentation allows exogenously delivered antigen to be loaded on MHC Class I 
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molecules resulting in presentation to CD8+ T cells, which are critical in cell-mediated 
immune responses [54, 55]. DCs, unlike macrophages, are able to prime naïve CTLs 
and helper CD4+ T cells using cross-presented antigens [52, 53, 56]. Presumably this is 
because DCs are the only cells that possess the necessary costimulatory signals, such 
as CD80 and CD86, required for T cell activation. Activation of naïve CD4+ and CD8+ T 
cells, leads to T cell proliferation and their transition into effector cells [49, 57].   
Interactions with other antigen-presenting cells 
DCs, highly acknowledged for their T cell interactions, are also fundamental in 
directing B cell growth, differentiation and immunoglobulin production [24]. B cells can 
be influenced by DCs indirectly through the release of cytokines from DCs and T cells, 
as well as directly though cell-cell interactions [58]. There may also be a role for 
macrophages in enhancing DC antigen presentation. Dendritic cells have been shown 
to develop antigen-specific T cell responses from antigenic peptides generated by 
macrophages [59, 60].  
 
Dendritic cell vaccines-successes/failures 
Ex vivo DC-based vaccines  
Given their central role in controlling cellular and humoral immunity, dendritic 
cells represent a logical target for antigen delivery and therapeutic vaccines against 
intracellular infections and cancer. DC targeting has historically been dominated by the 
ex vivo approach. This approach involves isolating dendritic cells present in the patient’s 
blood, stimulating the DCs with selected antigen(s) and/or maturation stimuli ex vivo, 
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and then reinjecting those modified DCs into the patient with the intention of inducing 
antigen-specific B and T cell responses. Thousands of reports have published clinical 
findings based on the in vitro priming of DCs with antigen, however most of these DC-
based vaccines did not progress past Phase II clinical trial testing [51]. The only vaccine 
that proved the ex vivo approach to be a success came in 2010 by FDA approval of 
Sipuleucel-T, a DC-based vaccine for prostate cancer [61]. Several issues may explain 
the lack of success using this vaccination approach, including uncertainty in the route of 
cell administration and numbers of DCs to inject, shortage of TLR agonists (to induce 
DC maturation), choice of antigen and clinical testing primarily on late-stage cancer 
patients [62, 63]. Addition concerns relate to the high costs and labor-intensive aspect 
of the personalized vaccine therapy. Overall, what these DC-based vaccine trials did 
show is that they were safe, well tolerated by patients and capable of inducing potent 
immune responses in some cases [49] (Table 1.2). 
In vivo DC-based vaccines 
 Exploiting DCs for vaccination has largely turned to in vivo targeted approaches. 
Intensive research on DC biology has identified cell surface receptors that are more or 
less DC-specific, allowing for an opportunity to target these APCs directly (Table 1.3). 
Options for DC targeting include the use of: antibodies for DC-specific surface 
molecules, ligands to bind to DC-specific surface molecules, and DC-specific liposome 
or virosome preparations. Antibodies for receptors have the potential to be highly 
specific targeting moieties.  In mice, antibody-fused antigen is hundreds of times more 
efficient than untargeted antigens and offers options for antigen presentation on both 
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MHCI and MHCII molecules to CD8+ and CD4+ T cells, respectively [64, 65]. Particles 
bound to anti-DEC205 or anti-CD11c also show enhanced uptake by DCs compared to 
control particles in vivo [66], resulting in protection against tumor growth in mice [67, 
68]. However, antibody-based targeting faces numerous drawbacks, including their 
higher cost to develop and the potential to negatively affect antibody affinity by addition 
of a conjugate.  Even if these challenges could be overcome, the antibody-based 
targeting method still relies on the addition of another molecule (cytokine, interleukin, 
PAMP) to the formulation in order to promote immunity rather than tolerance [65, 69, 
70].  Other studies have shown that conjugating a ligand for a DC-specific cell surface 
receptor results in enhanced antigen-specific responses [71-73]. Although ligands for 
the DC-SIGN receptor on DCs are known, they are rather complex, which would 
ultimately place a burden on the development of a vaccine. To conclude, a few 
approaches to target DCs have proved promising in harnessing DCs’ immunogenicity, 
yet there still is room for improvement in terms of simpler preparation and cost.  
 
Multicomponent vaccine delivery carriers 
Delivery systems themselves can be classified as adjuvants due to their abilities 
to target material to APCs, target antigen to the cytosol, and protect antigen from 
degradation. The combination of these abilities can improve the immune response while 
reducing the amount of antigen needed. 
	 14		
Co-delivery of antigen and adjuvant  
Traditional vaccines comprised of soluble antigen formulated with alum or in an 
emulsion form have not been practical for combatting infections that require robust 
cellular immune responses. Soluble antigen is typically weakly stable and has low 
bioavailability [74]. By formulating soluble antigen and adjuvant into a particulate carrier, 
antigen can be protected from degradation. In addition, previous work has shown that 
delivering antigen and adjuvant to the same APC via a nanoparticle carrier can enhance 
both humoral and cellular immune responses [75-77]. Further, delivery of antigen and 
adjuvant to the cytosol of cells generates enhanced cellular immunity and Th1 
responses [78]. An inherent advantage of using a carrier to deliver antigen is the 
versatility of the delivery system. Multiple antigens can be encapsulated to enhance 
overall specific immune responses towards the target pathogen and additional 
incorporation of adjuvant(s) such as TLR or CLR ligands into the carrier would allow for 
selective tailoring of immune responses.  
Mediating endosomal escape via Listeriolysin O (LLO) 
Proteins ingested by cells are typically degraded in the endosome and loaded 
onto MHC Class II molecules for presentation to CD4+ T cells. Proteins cannot readily 
access the cytosol for loading onto MHC Class I molecules and presentation to CD8+ T 
cells. To enhance antigen delivery to the cytosol, a bacterial hemolysin from Listeria 
monocytogenes (Lm), listeriolysin-O (LLO), can be co-encapsulated with antigen in 
liposomes [79-81]. When Lm is phagocytosed, LLO protein is secreted into the host’s 
endosomal compartment. At pH 5.5, conditions present in the acidifying endocytic 
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pathway, LLO is most active and forms pores in the endosomal membrane by binding 
membrane cholesterol and oligomerizing, thus facilitating the bacteria’s escape into the 
cytosol [82]. How LLO secretion forms pores in the endosomal membrane is not 
completely elucidated but the presence of two bacterial phospholipases PI-PLC and PC-
PLC may be additionally required to enhance release of the endosomal components 
[83, 84]. Nevertheless, it has been shown that using purified LLO, co-encapsulated with 
antigen and adjuvant, delivers antigen to the cytosol of APCs [78, 85].  
 
Liposome uptake and the generation of long-circulating liposomes 
Liposome carriers 
Liposomes are particularly appealing as a vaccine carrier because a liposome’s 
size and shape resembles that of viral particles, which are naturally targeted for uptake 
by APCs. Liposomes are also useful platforms for delivery of materials, with their 
hydrophobic bilayer and aqueous center enabling these carriers to encapsulate both 
hydrophilic and hydrophobic cargo. The liposomal membrane additionally provides 
protection of encapsulated cargo from recognition by neutralizing antibodies and 
degradation by blood serum proteins. However, the attractiveness of liposomes as a 
carrier diminishes greatly when delivery of material requires bypassing macrophage 
uptake in the MPS (mononuclear phagocyte system) (i.e., delivery of antigen to 
peripheral tissue including lymph nodes). Conventional liposome formulations have 
circulation half-lives that can vary from a few minutes to multiple hours (depending on 
the dosage, particle diameter, surface charge, and bilayer fluidity) as a result of their 
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rapid uptake into the cells of the MPS [86]. Thus, conventional liposomes’ therapeutic 
use has been limited to applications involving delivery of drugs to this system (i.e., 
spleen and liver). The use of glycolipids and hydrophilic polymers in the liposome 
formulation has been proven to decrease uptake of liposomes by the mononuclear 
phagocyte system [86, 87]. 
Long circulating liposomes 
 Regardless of the administration route, antigens and vaccine carriers, 
particularly nanosized carriers, are avidly taken up by local macrophages and by 
macrophages of the MPS when introduced into systemic circulation. It was discovered 
that some anionic lipids incorporated into conventional liposome formulations could alter 
circulation half-life by reducing macrophage uptake of liposomes in the spleen and liver 
[88]. All anionic lipids are not capable of reducing macrophage uptake; while 
phosphatidylserine (PS) or phosphatidylglycerol (PG) reduce liposome half-life in vivo to 
minutes, the glycolipids phosphatidylinositol (PI) or monosialotetrahexosylganglioside 
(GM1) results in prolonged half-lives [88-91]. Liposomes with anionic lipids that 
markedly reduce macrophage uptake by the MPS were termed long circulating 
liposomes. Compared to neutral liposomes, negatively charged liposomes had once 
been strictly associated with decreased circulation times and increased uptake by cells 
[92, 93]. However, the realization that incorporating negatively charged GM1 and PI 
lipids could reduce liposomal uptake by macrophage cells offered up a different theory 
to explain anionic liposomes and their interactions with cells. To explain this 
discrepancy, anionic lipids can be divided into two categories. For example, PS and PG 
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lipids, which reduce half-life in vivo, have negatively charged groups that are exposed to 
the environment on the outer surface of the liposome. This may allow for direct 
interaction between the negatively charged group on the liposome surface and either 
plasma proteins or cell-surface proteins, thus accelerating liposome clearance. In the 
case of both GM1 and PI, a bulky hydrophilic group is thought to shield the negative 
charge and reduce liposome interaction with opsonizing proteins [88]. The affinity of 
divalent calcium ions in the blood to exposed negatively charged lipid head groups may 
also play a role in liposome aggregation and instability [94, 95]. A shielded negative 
charge in that case would prevent vesicle aggregates and deter rapid clearance [88].  
 The main purpose of long-circulating liposomes, including PI- and GM1-
containing liposomes, at the time of their development was to deter the macrophage 
uptake (by the MPS) of liposomes after intravenous injection. This allowed for increased 
numbers of liposomes to travel through the MPS, ultimately reaching peripheral tissues, 
especially tumor [86]. Delivery to tumor via lipid nanoparticles was a challenge before 
long-circulating liposomes, however with their development, encapsulated 
chemotherapeutics could now be delivered directly to tumor tissues [96, 97]. The unique 
ability of long-circulating liposomes to deter rapid macrophage uptake in vivo has 
additional potential in the context of vaccine design. Directing antigen-containing 
liposomes away from dominant macrophage uptake may facilitate potential interaction 
and uptake by DCs in the body. When long circulating liposomes were developed, there 
was scarce knowledge of dendritic cells and their functions. In the past 40 years, DCs 
have become a well-characterized cell type known for its distinct and fundamental role 
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in the immune response. Yet, interactions between long circulating liposome 
formulations and DCs have not been studied in detail. The behavior of PI- and GM1-
containing liposomes has also not been previously studied after subcutaneous injection, 
which would be a preferable route of administration for vaccines. 
 
Conclusion 
 Directing more antigen to dendritic cells, away from macrophages, has the 
potential to improve immune responses to subunit protein vaccines. Directly targeting 
antigen (and adjuvant(s)) to dendritic cells using DC-specific antibodies or ligands 
specific for DC surface receptors are expensive, labor-intensive targeting approaches.  
We embraced the idea that long-circulating liposome formulations, capable of reducing 
initial rapid macrophage uptake, may be useful for passively targeting DCs in peripheral 
tissues such as the lymph nodes, where DCs are in high numbers and close proximity to 
effector immune cells. Increasing the antigen uptake by DCs ever slightly could have a 
profound effect on T and B cell activation, proliferation and immune stimulating 
properties, which may enhance the immunogenicity of a liposomal subunit protein 
vaccine preparation.  
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Pathogen Type of vaccine 
Vaccine-induced 
protective 
immunity 
Mechanisms of immune 
control during infection 
 
Virus 
Smallpox Live Antibodies, CTL CTL 
Rabies Killed virus Antibodies Antibodies, CD4, CTL 
Polio Live or killed virus Antibodies Antibodies 
Measles Live Antibodies, CTL Antibodies, CD4, CTL 
Mumps Live Antibodies Antibodies 
Rubella Live Antibodies Antibodies 
Varicella zoster Live Antibodies, CTL Antibodies, CTL 
Haemophilus 
influenza type B 
Hib-conjugated 
polysaccharide Antibodies NA 
Influenza Protein Antibodies Antibodies, CD4, CTL 
Hepatitis A Killed virus Antibodies Antibodies, CD4, CTL 
Hepatitis B Protein Antibodies Antibodies, CD4, CTL 
Human 
papillomavirus VLP or protein Antibodies CD4, CTL 
Bacteria/Toxoid 
Diphtheria Toxoid Antibodies NA 
Tetanus Toxoid Antibodies NA 
Pertussis Acellular Antibodies NA 
Bacillus Calmette-
Guérin (BCG) Live Antibodies, CTL Antibodies, CD4, CTL 
Typhoid (Ty21a) Live Antibodies, CTL Antibodies, CD4, CTL 
CD4, CD4+ T cell; CTL, cytotoxic T lymphocyte; NA, not available 
 
Table 1.1 Correlates of immune protection (adapted from (9) and (10)) 
 
All currently licensed vaccines in the United States established protective immunity 
based on antibody responses following immunization. Further studies have indicated 
that CD4+ and CD8+ (CTL) T cell responses play a role in protection for several 
vaccines.  
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Vaccine and antigen Indication Key observations 
GM-CSF–IL-4 DCs with or 
without HLA-A*0201-restricted 
peptides or peptides alone 
Metastatic prostate 
cancer 
Immunogenicity of DCs 
GM-CSF–IL-4 DCs with 
peptides, tumor lysates or 
autologous tumor-eluted 
peptides 
Stage IV melanoma, 
renal cell carcinoma 
and malignant glioma 
Loading DCs with complex antigen 
preparations 
Blood DCs and idiotype 
antigens 
Multiple myeloma • Immunogenicity of DCs 
• Tumor regression 
Mature GM-CSF–IL-4 DCs 
and peptides 
Stage IV melanoma • Well-controlled and validated 
vaccine manufacture process 
• Testing mature DCs 
• Immunogenicity 
CD34+ HPC-derived DCs and 
peptides 
Stage IV melanoma • Loading vaccines with a mixture of 
well-defined peptides 
• Durable immune responses in long-
term survivors 
FLT3 ligand-expanded blood 
DCs and altered peptides 
Advanced 
CEA+ cancer 
Immunogenicity 
Immature GM-CSF–IL-4 DCs Healthy volunteers Antigen-specific inhibition of effector 
T cell function after injection of 
immature DCs 
GM-CSF–IL-4 DCs and tumor 
lysates 
Refractory paediatric 
solid tumors 
Immunogenicity 
Mature cryopreserved GM-
CSF–IL-4 DCs 
Stage IV melanoma Immunogenicity 
DCs loaded with autologous 
tumor RNA 
Colon cancer • Feasibility 
• Immunogenicity 
DCs loaded with killed 
allogeneic tumor cells 
Stage IV melanoma • Immunogenicity 
• Durable objective clinical responses 
• Long-term survival 
Monocyte-derived DCs loaded 
with the NK T cell ligand α-
galactosylceramide 
Advanced cancer Adjuvant effect of NK cell activation 
on CD8+ T cell-mediated immune 
response 
Monocyte-derived DCs Melanoma In vivo identification of antigen-
specific immune response by PET 
imaging in patients 
    Route of DC administration affects T 
cell activation 
 
 
Continued on next page 
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Vaccine and antigen Indication Key observations 
Comparative study of 
CD34+ HPC-derived LCs 
versus monocyte-derived DCs 
Melanoma LC-based vaccines stimulated 
significantly greater tyrosinase-HLA-
A*0201 tetramer reactivity than the 
monocyte-derived DC vaccines 
Type 1-polarized monocyte-
derived DCs 
Glioma Combination of DC vaccination with 
polyICLC to trigger systemic 
inflammation driven by type I 
interferon family members 
CEA, carcinoembryonic antigen; DC, dendritic cell; IL-4, interleukin-4; GM-CSF, granulocyte-
macrophage colony stimulating factor; HLA, human leukocyte antigen; HPC, haematopoietic 
progenitor cell; LC, Langerhans cell; NK cell, natural killer cell; PET, positron emission 
tomography; polyICLC, polyinosinic-polycytidylic acid stabilized with poly-L-lysine and 
carboxymethylcellulose 
 
Table 1.2 Examples of clinical trials testing vaccination with ex vivo DCs (adapted 
from (49)) 
Studies using ex vivo generated DCs proved that dendritic cell therapies were safe, well 
tolerated and generally effective.  	
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Targeted  
receptor 
Receptor 
family Expression by human cells 
Mannose 
receptor CLR 
iDCs (low on mDCs), monocytes, macrophages, 
subsets of endothelial cells, retinal pigment epithelium, 
kidney mesangial cells, tracheal smooth muscle cells 
CD205 
(DEC-205) CLR 
mDCs (low on iDCs), thymic epithelial cells, 
monocytes, B cells, NK cells, T cells 
DC-SIGN CLR iDCs (low on mDCs), macrophages, megakaryocytes 
LOX1 CLR iDCs, macrophages, fibroblasts, smooth muscle cells, endothelial cells 
Dectin-1 CLR 
iDCs (low on mDCs), monocytes, macrophages, 
neutrophils, eosinophils, B cells, subpopulation of T 
cells 
FcϒRI FcR DCs, monocytes, macrophages, activated neutrophils 
FcϒRIIa FcR DCs, monocytes, macrophages, neutrophils, eosinophils, platelets 
FcϒRIII FcR DCs, NK cells, macrophages, neutrophils, stimulated eosinophils 
FcϒR FcR mDCs (low on iDCs), monocytes, macrophages, neutrophils, eosinophils 
CD11c–
CD18 Integrin 
DCs, monocytes, macrophages, granulocytes, NK 
cells, activated B cells, certain CTLs 
MACI Integrin DCs, monocytes, macrophages, granulocytes, NK cells, subsets of T and B cells 
CD40 TNF-receptor superfamily 
DCs, B cells, macrophages, endothelial cells, 
keratinocytes, fibroblasts, CD34+haematopoietic cell 
progenitors, thymic epithelial cells 
Siglec-H Siglec No human orthologue identified 
CLR, C type lectin receptor; CTLs, cytotoxic T lymphocytes; DC, dendritic cell; FcR, Fc 
receptor; iDC, immature dendritic cell; mDC, mature dendritic cell; NK cell, natural killer 
cell; TNF, tumor necrosis factor;  
 
Table 1.3: Dendritic cell surface receptors used for targeting of antigen to DCs 
(adapted from (63))  
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Figure 1.1 Dendritic cell subsets: their phenotypes and functions (adapted from 
(51)) 
 
Dendritic cells are a heterogeneous cell type with multiple roles in the immune 
response.    
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CHAPTER 2 
Uptake Behavior of PI- and GM1-Containing Liposomes in Macrophage and 
Dendritic Cell Types 
 
SUMMARY 
 Targeting dendritic cells (DCs) with nanoparticles in vivo is not an easy feat. 
Macrophage uptake is generally accepted as the main route of nanoparticle clearance in 
the body due to macrophage’s high phagocytic capability. We hypothesized that 
incorporating either phosphatidylinositol (PI) or monosialotetrahexosylganglioside (GM1) 
glycolipids into a liposome formulation would lead to enhanced DC uptake, especially in 
the peripheral lymph nodes. This presumed enhanced DC update would result from 
decreased initial macrophage uptake previously characterized in these two long-
circulating liposome formulations. Using simple liposome formulations consisting of 
dioleoylphosphatidylcholine (DOPC), cholesterol (Chol), and either PI or GM1 
glycolipids, we examined the in vitro and in vivo uptake of these liposome formulations 
by DCs and macrophages. In vitro studies of liposome formulations using cultured cell 
lines or primary cells indicate liposomes containing PI at 10 mole percentage (mol%) 
(PI-liposomes; PI-lip) have increased uptake in DCs compared to liposomes containing 
10mol% GM1 (GM1-liposomes; GM1-lip), whereas macrophage uptake was 
comparable. In vivo uptake by mouse lymph node (LN) DCs and macrophages was 
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determined 4 hours and 24 hours after subcutaneous (s.c.) injection of liposomes. 
Supporting in vitro results, DCs in the lymph node internalized more PI-lip than GM1-lip 
in a 4-hour time period. In contrast to uptake trends described in vitro, PI-lip also 
exhibited higher uptake than GM1-lip by LN macrophages after 4 hours. LN uptake of 
PI-lip was diminished after 24 hours; however, there was no significant change in 
uptake of GM1-lip by LN DCs between 4 and 24 hours post injection. In addition, 
macrophage uptake of GM1-lip was higher than that for PI-lip 24 hours post injection, 
suggesting GM1-liposomes persist in the lymphatic system over this time period. In 
summary, by slightly altering liposome composition we show increased initial DC uptake 
of liposomes using PI-liposomes or alternatively, GM1-liposomes can be utilized to 
facilitate longer exposure of liposomes with DCs and macrophages. 
 
INTRODUCTION 
Developing vaccines against viral infections and/or cancer will require potent 
immune responses capable of detecting and clearing infected or tumor-causing cells. 
Clearance of intracellular viruses and cancerous cells from the body necessitates cell-
mediated immune responses, especially activation of CD8+ T cells (CTL), which can 
directly kill targeted cells [1, 2]. Live vaccination stimulates CTL activity; however, safety 
issues including reversion to a virulent species outweigh the benefits of live attenuated 
vaccines [3, 4]. Subunit protein vaccines are inherently safer than live vaccines but their 
use has been limited, as many do not confer protective immunity against the pathogen. 
This decreased effectiveness is partially due to the short half-lives of soluble protein in 
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vivo, as well as a general lack of activation of antigen-presenting cells (APCs) of the 
immune system, which is important for promoting immunity rather than antigen 
tolerance [5]. Further absent in subunit protein vaccines is the generation of CD4+ or 
CD8+ T cell-mediated immune responses [6]. There are a few approaches to improve 
upon this drawback of subunit protein vaccines, including the use of molecular 
adjuvant(s) to enhance and/or tailor immune responses, incorporating a delivery vehicle 
(e.g. emulsions, nanoparticles), or targeting of antigen to specific areas or cells in the 
body in order to enhance the immune response [7-9]. All of these approaches rely on 
APCs to enhance the immune response.  
APCs are special cells of the immune system that recognize, internalize, process, 
and present antigen to T cells, including CTLs. Dendritic cells and macrophages are 
both APCs that have interrelated roles in the immune response. Dendritic cells and 
macrophages are situated at high numbers in the most common areas where foreign 
entities may be introduced (e.g. skin, and mucosal surfaces) and also in the lymph 
nodes, where they propagate immune responses to T and B cells [10]. Macrophages 
are highly active in phagocytosis yet seem more suitable for destruction of 
phagocytosed material, rather loading of antigenic peptides for presentation to T cells 
[11, 12]. Dendritic cells (DCs), discovered in 1973, are distinct from monocytes and 
macrophages phenotypically and functionally [13, 14]. Their unique and integral role in 
the immune response is of high interest in the field of vaccine development. DCs are 
well known for their efficient T cell activation, which makes them a prime target for 
vaccines in need of potent T cell responses. DCs can initiate T cell responses with few 
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numbers of cells and also small amounts of antigen [11, 12, 15]. Therefore, skewing 
antigen uptake even slightly towards DCs, may augment immune responses after 
immunization. 
 To harness the immune-stimulating capabilities of DCs, some antigen must be 
directed away from the dominant phagocytic cells in the body (i.e. macrophages). DC-
specific cell surface receptors such as DEC-205, DC-SIGN, and CD11c have been 
utilized for DC-targeted antigen delivery. Conjugating either ligand or antibody for these 
receptors to antigen or antigen-delivery vehicles has demonstrated the value of DC-
specific targeting. Studies have shown antigen delivery specifically to DCs can improve 
antigen-presentation and T cell activation, as well as provide clinically relevant 
decreases in tumor size after treatment [16-20]. Although these methods have shown 
the benefit of DC-targeting, they are ultimately too complex for a large-scale vaccination 
program. Ligands of DC-SIGN are complex carbohydrate structures inferring high costs; 
likewise, antibody production for targeting of these DC receptors is not economical.  
Although liposomes are biocompatible, they are still recognized by the immune 
system as foreign bodies. Therefore, their main route of clearance from the body comes 
from phagocytes, specifically macrophages. Decades ago, the use of liposomes was 
limited due to the unavoidable high uptake by macrophages in the mononuclear 
phagocyte system (MPS), which includes the spleen and liver. Liposome cell uptake is 
dependent on many factors including size, lipid composition and overall charge of the 
particles. It was discovered that some anionic lipids incorporated into conventional 
liposome formulations could alter circulation half-life by reducing macrophage uptake of 
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liposomes in the spleen and liver [21]. All anionic lipids are not capable of reducing 
macrophage uptake; while phosphatidylserine (PS) or phosphatidylglycerol (PG) reduce 
liposome half-life in vivo to minutes, the glycolipids phosphatidylinositol (PI) or 
monosialotetrahexosylganglioside (GM1) results in prolonged half-lives averaging 16-24 
hours [21-25]. Incorporation of PI at minimum 9 mol% or GM1 at minimum 7 mol% of 
phospholipid in a liposome formulation deterred liposome uptake by macrophages and 
increased half-life [23, 26]. Even at identical mole percentages (mol%) in liposomes, PS, 
PG, PI and GM1 lipids had remarkably different uptake characteristics by macrophages. 
To rationalize these data, it was postulated that because PI and GM1 have bulky 
hydrophilic head groups their negative charge is shielded from recognition by serum 
proteins whom opsonize particles [21]. Furthermore, the cell membranes of most cells in 
the body contain glycolipids, rendering them negatively charged and hydrophilic, a 
property that is thought to be in part responsible for the long-circulating properties of PI- 
and GM1-containing liposomes [25].  
Conventional liposomes compositions not containing PI or GM1 have rapid 
extensive uptake by macrophages in the MPS after intravenous injection, resulting in 
short half-lives and limited use as delivery vehicles. The identification of long-circulating 
liposomes, including PI- and GM1-containing liposomes, was a significant improvement 
in liposome technology. PI- and GM1-containing long-circulating liposome formulations 
are well described for reducing the uptake by macrophages of the MPS, but their uptake 
was not studied in dendritic cells. PI- and GM1-containing long-circulating liposome 
formulations were of interest because it was hypothesized that deterring initial high 
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macrophage uptake would benefit liposome uptake by DCs, especially in the periphery 
(i.e. lymph nodes rich in DCs). The possibility of reduced initial macrophage uptake 
using PI- or GM1-containing liposome formulations was of interest for promoting DC 
uptake of liposomes. Coupled with easy preparation and inexpensive materials required, 
presented PI- and GM1-liposomes as promising vaccine delivery systems. However, 
these liposome formulations have not been studied after subcutaneous injection, which 
would be a preferable route of administration for vaccines. 
Dendritic cells in the lymph node (LN) are strategically positioned to generate 
immune responses. Here, DCs in high numbers are in close proximity to T and B cells 
promoting cell-cell interaction and propagating the immune response [10, 27]. A majority 
of lymph node DCs are immature, meaning they are efficient at internalizing and 
processing antigen [28]. Therefore, liposomes that gain access to the lymph nodes 
through the lymphatic vessels could augment uptake by DCs and potentially enhance 
immune responses to antigen. Subcutaneously administered liposomes can be taken up 
via lymphatic capillaries into lymphatic vessels through which they travel to access 
lymph nodes. Any liposomes that are not captured by cells in the lymph nodes ultimately 
enter the blood stream and encounter organs such as the liver and spleen [29].  
Liposome size is the most crucial factor in determining uptake into lymphatic 
vessels, and therefore uptake into lymph nodes [30]. Small liposomes (mean diameter 
<0.1 μm) can gain access to lymph nodes quicker, but they also display higher blood 
concentrations suggesting they pass through the lymphatic system with low uptake by 
DCs in the lymph nodes. Larger liposomes (>0.4 μm up to 1 μm) have been detected in 
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the lymphatic system; however, a significant majority of these liposomes will remain at 
the injection site and have low uptake efficiencies [30, 31]. Studies suggest that 
nanoparticles smaller than 0.2 μm can drain into the lymph nodes and be taken up by 
DCs in the lymph node [32]. Size is also an important factor for liposomes to retain their 
long-circulating properties. Liposomes containing 10mol% GM1 had low uptake by liver 
and spleen in the size range of 70-200 nm while those larger than 300 nm 
predominantly accumulated in the spleen [33]. Moreover, liposomes containing 10mol% 
of either PI or GM1 lipid exhibited maximum blood/MPS ratios when mean diameter was 
80-120 nm [34]. 
 We hypothesized that small liposomes (mean diameter≈100nm) composed of 
either PI or GM1 glycolipid at 10mol% of total phospholipid would deter initial rapid 
macrophage uptake, in turn, facilitating liposome interaction with DCs for uptake. We 
demonstrated that PI-lip and GM1-lip have differential uptake by DCs in vitro and in 
vivo. In vitro PI-liposomes promoted uptake by DCs compared GM1-lip, whereas 
macrophage uptake was comparable between PI- and GM1-liposome formulations. In 
vivo PI-lip also exhibited enhanced uptake by lymph node DCs within a short period 
after liposome injection. Contrastingly, GM1-liposomes show less initial uptake by lymph 
node DCs and macrophages in vivo but may be better suited for extended exposure of 
liposome and potential cargo with LN cells. These glycolipid-bearing liposomes are easy 
to prepare and liposome properties are reproducible, which places additional value on 
these liposome formulations as potential protein subunit vaccine carriers.  
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MATERIALS AND METHODS 
Liposome preparation 
Cholesterol (Chol) was obtained from Calbiochem (La Jolla, California). All non-
fluorescent lipids were obtained from Avanti Polar Lipids (Alabaster, Alabama). Oregon 
Green® 488 1,2-Dihexadecanoyl-sn-Glycero-3 Phosphoethanolamine (Oregon 
Green 488-DHPE) was obtained through Life Technologies  (Grand Island, New York). 
Liposomes were prepared at a 2:1 molar ratio of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (Δ9-cis) (DOPC) to Chol. In uptake experiments, Oregon Green 488-
DHPE lipid was incorporated at 1mol% of the total phospholipid. L-α-
phosphatidylinositol (Soy) (PI), monosialotetrahexosylganglioside (ovine brain) (GM1), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (PEG-PE) or L-α-phosphatidylserine (porcine brain) (PS) was incorporated at 
indicated mol% of the total phospholipid. pH-sensitive liposomes contained L-α-
phosphatidylethanolamine (egg, chicken) (ePE) and cholesteryl hemisuccinate 
(CHEMS) (Sigma-Aldrich) at a 2:1 molar ratio. Lipid mixtures were dried into a lipid film 
using a Buchi Rotavapor R-200 rotary evaporator. Lipids were dried completely then 
rehydrated with isotonic (290 ± 10 mmol/kg osmolality) HEPES-buffered saline 
containing EDTA (HBSE) (10mM HEPES, 140mM NaCl, 1mM EDTA, pH 7.4). pH-
sensitive liposomes composed of ePE:CHEMS were hydrated in HBSE, pH 8.4 buffer. 
Hydrated lipid films were vortexed, subjected to 5 freeze/thaw cycles and extruded 
using double-stacked polycarbonate 100 nm diameter filters (GE). The size of the 
liposomes and zeta potential was determined using a Malvern ZS90 ZEN 3600 
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zetasizer. Phospholipid content of liposomes was quantified using Bartlett’s phosphate 
assay[35]. Determined phospholipid concentrations signified the concentration of 
liposomes and were used in the dosing calculations. GM1 does not have a phosphate 
group and thus the phospholipid assay concentrations determined do not include GM1 
content of the liposomes; dosing calculations were adjusted to account for this. 
Prepared liposome samples were stored at 4°C and used within 10 days of preparation. 
 
Cell culture 
All tissue culture media and reagents were purchased from Invitrogen (Carlsbad, 
CA) unless otherwise noted. All cells were maintained in in a humidified incubator at 
37°C and 5% CO2. J774A.1 mouse macrophages (ATCC TIB-67) and JAWSII mouse 
dendritic cells (ATCC CRL-11904) were purchased from ATCC (Manassas, Virginia).  
J774 cells were maintained in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% heat-inactivated FBS (HI-FBS) and 100μg/mL streptomycin, 
100U/mL penicillin. JAWSII cells were maintained in alpha minimum essential medium 
with ribonucleosides and deoxyribonucleosides supplemented with 20% HI-FBS, 100 
μg/mL streptomycin, 100U/mL penicillin, 2mM L-glutamine and 5ng/ml murine GM-CSF 
(PeproTech, Inc. Rocky Hill, New Jersey).  
Bone marrow was harvested from femurs and tibia of female C57BL/6 mice and 
differentiated into bone marrow-derived macrophages (BMMs) and bone marrow-
derived dendritic cells (BMDCs). BMM media (DMEM supplemented with 20% HI-FBS, 
30% L-929 cell conditioned media containing macrophage colony stimulating factor (M-
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CSF), 2mM glutamine, 100μg/mL streptomycin, 100U/mL penicillin and 55μM 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO)) was used to maintain the BMM 
cultures. BMMs were derived as described previously by Stier et al [36]. In short, 
precursor cells were cultured for 6 days in the presence of M-CSF, a component of the 
L-cell media supplement. Cells were replenished with new cell media on day three of 
culture. BMMs were then harvested on day six of culture and stored in liquid nitrogen 
until needed. BMDC media (RPMI-1640 supplemented with 10% HI-FBS, 100μg/mL 
streptomycin, 100U/mL penicillin, and 50μM 2-mercaptoethanol) was prepared and 
murine GM-CSF was added fresh each time to the BMDC media at 20ng/ml immediately 
before use. Cells were cultured in the presence of GM-CSF for 6 days, exchanging the 
cell media every 2 days, after which loosely adherent and non-adherent cells were 
harvested and stored in liquid nitrogen until needed.  
 
In vitro cell uptake and flow cytometry cell staining 
 Equal counts of cells were incubated with liposomes at 100μM [phospholipid] in 
serum-free DMEM for one hour at 37°C, unless otherwise noted. After treatment, any 
non-cell bound liposomes were removed by centrifugation and three subsequent cell 
washes in phosphate buffered saline (PBS) pH 7.4. Cell samples to be stained for flow 
cytometry were allowed to incubate in PBS containing 10% HI-FBS for 30 minutes at 
room temperature before addition of staining antibodies. The cell samples to be labeled 
with antibodies were incubated with murine anti-CD11b-PerCPCy5.5 antibody (Ab) (BD 
Pharmingen) and murine anti-CD11c-PE Ab (BD Pharmingen) at 4°C for 30 minutes to 
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one hour. Prior to flow cytometry analysis, cell samples were thoroughly washed using 
PBS/10% HI-FBS to remove any non-bound antibodies from the sample. Cell 
fluorescence was obtained using a BD FACSCalibur flow cytometer (San Jose, CA). 
Cell Quest software was used to plot fluorescence values and obtain the mean 
fluorescence intensity (MFI) of samples.  
 
Mice 
C57BL/6 (7-8 weeks old; Jackson Laboratories, Bar Harbor, ME) were used in 
this study and handled according the University of Michigan Institutional Animal Care 
guidelines. Mice were injected subcutaneously (s.c.) on each side of the hind flank near 
the tail base with a total of 250 nmoles phospholipid in 100 μL volume. 
 
Preparation of lymph nodes and flow cytometry 
 Inguinal lymph nodes harvested from mice were sliced and squeezed through a 
70-μm filter to prepare a single cell suspension in PBS containing 1% bovine serum 
albumin (BSA). Cell suspensions were washed with PBS/ 1%BSA then incubated with 
CD16/32 Fc block (eBioscience, San Diego, CA) for 10 minutes at RT and a small 
amount of each sample was taken for negative and single-label controls. Cells were 
then incubated with murine anti-CD11b-PerCPCy5.5 Ab (BD Pharmingen) and murine 
anti-CD11c-PE Ab (BD Pharmingen) for 1 hour on ice. Prior to flow cytometry analysis, 
cell samples were thoroughly washed using PBS/1% BSA to remove any non-bound 
antibodies from the sample. Cell fluorescence was obtained using a BD FACSCalibur 
	 45	
flow cytometer (San Jose, CA). Cell Quest software was used to plot fluorescence 
values and obtain the MFI of cell samples. 
 
RESULTS  
JAWSII dendritic cells exhibit preferential uptake of PI-liposomes 
 Previous investigations of liposome formulations containing a 2:1 ratio of 
phosphatidylcholine (PC) to cholesterol (Chol) and either PI or GM1 glycolipid focused 
exclusively on macrophages’ role in liposome clearance. With increasing evidence of 
DCs’ fundamental role in the immune system we sought to examine the uptake of these 
liposome formulations in macrophage (J774) and dendritic (JAWSII) cell lines. 
Liposomes containing a 2:1 ratio of dioleoylphosphatidylcholine (DOPC) to Chol with 
10mol% of the total phospholipid being PI glycolipid are termed PI-liposomes (PI-lip). 
Liposomes containing a 2:1 ratio of DOPC:Chol with 10mol% of the total phospholipid 
being GM1 glycolipid are termed GM1-liposomes (GM1-lip). Liposomes containing only 
DOPC and Chol (DOPC:Chol liposomes) represent a neutrally charged liposome 
formulation that was additionally studied to assess baseline liposome uptake by both 
cell types. The DOPC:Chol liposomal formulation additionally containing 50mol% PS 
(PS-lip) was treated as a positive control, with evidence that PS displayed on 
nanoparticles promotes uptake by phagocytic cells [37]. Table 2.1 list the physical 
characteristics of the liposomes used in the following studies. Liposome uptake was 
monitored by fluorescence of OregonGreen488-DHPE lipid incorporated at 1mol% of 
the liposome composition and measured using flow cytometry. Overlaid histogram plots 
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as seen in Figure 2.1A and 2.1B plot cell fluorescence (X) vs. cell counts (Y). The x-
axis, fluorescence, is here-within always plotted on a log scale. The high cell uptake of 
PS-lip was comparable in J774 macrophages and JAWSII DCs, confirming both cell 
lines examined in the study are proficient at internalizing liposomes (Figure 2.1A and 
2.1B). The observed uptake of GM1-lip was similar to DOPC:Chol neutral liposome 
uptake regardless of cell type (Figure 2.1A and 2.1B). DCs incubated with PI-lip 
displayed increased cell-associated fluorescence compared to DCs exposed to GM1-lip 
(p<0.01) or DOPC:Chol liposomes (p<0.001) (Figure 2.1D), whereas in macrophages 
the uptake of these three liposome formulations were comparable (Figure 2.1C). 
Moreover, we also observed this exact result when the uptake experiment was 
performed with cells in the presence of serum-containing media (data not shown). The 
presence of serum is known to have dramatic effects on liposome uptake [24, 38]; 
overall, liposome uptake was reduced in both JAWSII and J774 cells but the trends in 
liposomal uptake described previously were upheld. 
 
Uptake trends in primary bone marrow-derived cells resemble those presented in 
cell lines 
 Uptake of PI-lip and GM1-lip was additionally examined in primary cells 
differentiated from progenitor cells in the bone marrow of mice. Primary cells were used 
for confirmation of studies performed in cell lines because, their behavior is expected to 
more closely resemble that of cells in vivo. Liposome uptake was monitored by 
fluorescence of OregonGreen488-DHPE lipid incorporated at 1mol% of the liposome 
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composition and measured using flow cytometry. A majority of bone marrow-derived 
DCs (BMDCs) cultured (≈60%) displayed CD11c and CD11b on the cell surface, 
indicating DC differentiation (data not shown). Cultured bone marrow-derived 
macrophages (BMMs) cultured displayed no CD11c, but had high presence of CD11b 
(data not shown). BMMs and BMDCs had higher cell-associated fluorescence than that 
seen with their respective cell lines, J774 and JAWSII. BMMs exhibit enhanced uptake 
of all liposomes formulations compared to BMDCs, albeit with no discernable uptake 
trends (Figure 2.2A and 2.2C). Fluorescence histograms for BMDCs appear to show 
GM1-lip is internalized less than DOPC:Chol liposomes, but the difference between the 
two mean fluorescence intensities (MFI) (108.8 ± 26.97  and 99.6 ± 2.96 respectively) is 
not considered significant at p<0.05 (Figure 2.2B). BMDCs exhibit markedly enhanced 
uptake of PI-lip (p<0.05) compared to GM1-lip and DOPC:Chol liposome formulations 
(Figure 2.2D). This study repeated at a lower liposome concentration (50μM) confirmed 
PI-lip has enhanced uptake compared to GM1-lip in BMDCs, a trend that was not 
observed in BMMs (data not shown). Studies performed in cell lines and primary cells 
offered the same results, confirmation that indeed, PI-lip formulations present DC-
specific targeting aspects in vitro. 
 
Uptake of PEG-lip is comparable to GM1-lip, in BMMs and BMDCs 
 Liposomes bearing a PEG polymer coating represent another approach to 
reduce uptake by macrophages in vitro and in vivo [25].  Poly (ethylene glycol) (PEG)–
phosphatidylethanolamine conjugates (PEG-PE) are incorporated into liposome 
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compositions to create a liposome with a hydrophilic, bulky surface polymer coating. 
PEG-PE was added to the DOPC:Chol lipid composition at 10mol% of total lipid (PEG-
lip), matching the amount of DOPC displaced by PI or GM1 glycolipids in their 
respective formulations. We sought to compare the uptake behavior of glycolipid-
bearing long-circulating liposomes (PI-lip and GM1-lip) to the polymer-coated long-
circulating liposome formulation. The uptake of GM1-lip, PI-lip and PEG-lip were 
compared in BMMs and BMDCs. Liposome uptake was monitored by fluorescence of 
OregonGreen488-DHPE lipid incorporated at 1mol% of the liposome composition and 
measured using flow cytometry. The uptake behavior of PEG-lip resembles that of GM1-
lip in macrophages and DCs, showing decreased uptake compared to neutral 
DOPC:Chol liposomes (Figure 2.3A and 2.3B). BMMs display slight, yet statistically 
insignificant (ANOVA p=0.0551) differences, between liposome formulations (Figure 
2.3C). However in BMDCs these uptake differences are clearly emphasized, especially 
when comparing PI-lip to PEG-lip (MFI=284.35 ± 9.85 and 81.04 ± 20.99 respectively, 
p<0.001) (Figure 2.3D).  The data indicate that the long-circulating characteristic of 
PEG-liposomes holds true in bone marrow-derived macrophage and dendritic cell types. 
 
Effect of PI density on liposome uptake by macrophages and DCs 
 To assess the contribution of PI lipid on the cellular uptake of liposomes we 
prepared four formulations with increasing PI mol%, starting with 0mol% PI (DOPC:Chol 
liposomes) as the lowest density and 50mol% PI as the highest density (Table 2.1). 
Liposome uptake was monitored by fluorescence of OregonGreen488-DHPE lipid 
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incorporated at 1mol% of the liposome composition and measured using flow cytometry. 
The increasing presence of PI glycolipid had dramatically different effects on liposome 
uptake by JAWSII DCs and J774 macrophages (Figure 2.4A and 2.4B). As described 
previously and shown again in Figure 2.4, liposomes containing 10mol% PI promote 
uptake by DCs whilst the impact on macrophage uptake is low. In the study presented, 
10mol% PI is the minimum and maximum amount needed to significantly enhance DC 
uptake (Figure 2.4B). Increasing PI content to 25mol% or 50mol% does not change 
uptake by JAWSII DCs. In contrast, for J774 macrophages, increasing PI content in the 
liposome formulation continuously improved liposomal uptake. At 50mol% PI in the 
liposome formulation liposomal uptake by J774 macrophages and JAWSII dendritic cells 
was similar (Figure 2.4C). 
 
ePE:CHEMS liposome compositions dissolve liposome uptake trends 
 Previously our lab group has used pH-sensitive liposomes composed of 
phosphatidylethanolamine and cholesteryl hemisuccinate (ePE:CHEMS liposomes) in 
combination with listeriolysin-O (LLO) protein from Listeria monocytogenes (Lm) to 
deliver encapsulated liposomal material into the cytosol of cells [36, 39, 40]. The ability 
to deliver antigen to the cytosol of APCs for subsequent presentation to CD8+ T cells 
would be optimal for a protein subunit vaccine formulation. We examined the influence 
ePE:CHEMS composition had on the uptake of liposomes also containing 10mol% 
glycolipid. Liposome uptake was monitored by fluorescence of OregonGreen488-DHPE 
lipid incorporated at 1mol% of the liposome composition and measured using flow 
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cytometry. Using ePE:CHEMS, rather than DOPC:Chol, increased the uptake of all 
liposome formulations tested regardless of cell type examined (Figure 2.5C and 2.5D). 
Interestingly, ePE:CHEMS liposomes containing 10mol% GM1 retained some aspect of 
reduced uptake in BMMs, when compared to ePE:CHEMS liposomes or ePE:CHEMS 
containing 10mol% PI (p<0.01) (Figure 2.5A). The presence of negatively charged 
CHEMS in the liposome formulations results in a high negatively charged liposome 
surface, which increased overall cell uptake of all ePE:CHEMS liposome compositions. 
This increase in cell association dissolved the advantage PI glycolipid had over GM1 in 
enhancing DC-specific uptake (Figure 2.5B and 2.5D).  
 
PI-lip promote uptake by macrophages and DCs present in the LN 
To further characterize the uptake of PI-lip and GM1-lip, their uptake by 
macrophages and DCs was analyzed in vivo. A total of 250 nmoles of the indicated 
liposome formulation (10mol% PI-lip, GM1-lip, or PS-lip; mean diameter≈100 nm) (Table 
2.1) were subcutaneously injected into female C57BL/6 mice (n=2 mice per liposome 
formulation). The basis for injecting 250 nmoles of phospholipid was to mimic the 
amount of lipid content injected in the immunization study performed with these 
liposome formulations (Chapter 3). Lymph node cells were analyzed 4 hours post 
injection. As in in vitro experiments, liposome uptake was monitored by fluorescence of 
OregonGreen488-DHPE lipid incorporated at 1mol% of the liposome composition and 
measured using flow cytometry. The cell surface receptors, CD11b and CD11c were 
used as identifiers of macrophage and DC populations. Dendritic cells present in the 
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lymph nodes (LN) were selected as staining positive for both CD11c and CD11b, as 
determined by cellular fluorescence. Macrophages in the lymph nodes were classified 
as having no CD11c staining and high CD11b staining. Identified DC and macrophage 
populations from the same overall lymph node cell population were then plotted for their 
fluorescence due to liposome internalization (OregonGreen488 fluorescence) (Figure 
2.6A and 2.6B).  
The percentages of cells displaying any liposome-related fluorescence was 
similar between all liposome formulations whether LN macrophages (~60% Liposome+ 
cells) or LN DCs (~20% Liposome+ cells) were analyzed (ANOVA p=0.14 DCs; p=0.41 
macrophages) (Figure 2.6D), however this result did not translate to similar uptake of 
liposome formulations by macrophages or DCs (Figure 2.6C). LN cells recognize and 
internalize liposomes with different efficiencies. To emphasize this point, the percentage 
of LN macrophage cells that displayed any liposomal fluorescence was approximately 
60% regardless of the liposome formulation; however, the average MFI value 
associated with PI-lip was two times higher than the average MFI value for GM1-lip. 
Another observation is more LN macrophages internalize liposomes than do LN DCs 
(p<0.01) (Figure 2.6D). After only 4 hours, 60% of macrophages had internalized 
liposomes, suggesting that the glycolipid-containing ‘long-circulating’ liposomes do not 
largely deter macrophage uptake in the same way described of them after i.v. 
administration.  
In contrast to cell culture experiments, evaluation of in vivo uptake determined PI-
lip (DC MFI=51.32 ± 1.385; macrophage MFI=241.9 ± 16.5) had enhanced uptake 
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compared to GM1-lip (DC MFI=32.52 ± 5.705; macrophage MFI=100.9 ± 42.07) in both 
LN DCs and LN macrophages. Compared to in vitro experiments, the ability of PI-lip to 
promote DC-specific uptake was weakened. However, PI-lip uptake trended higher than 
GM1-lip in LN DCs (p<0.05). The uptake of GM1-lip by LN macrophages was highly 
variable contributing to a p-value greater than 0.05 when comparing macrophage GM1-
lip to PI-lip uptake (p=0.062). Although we cannot statistically define PI-uptake is higher 
than that of GM1-lip in macrophages, uptake trends indicate GM1-lip had lower uptake 
by both cell types during the 4-hour exposure (Figure 2.6C). We additionally monitored 
the uptake of PS-liposomes by LN macrophages and DCs in vivo (Figure 2.6A and 
2.6B). The uptake of liposomes containing PS has been studied extensively in vitro and 
in vivo which is why we choose to compare the biodistribution of PS-lip (10 mol% PS) to 
the 10mol% glycolipid liposome formulations. After 4-hour uptake, PS-lip displayed 
mean uptake values between those of PI-lip and GM1-lip in both cell types examined 
(DC MFI=46.84 ± 7.255; macrophage MFI=131.1 ± 16.22). ANOVA post-hoc multiple 
comparison tests determined there were no significant differences in uptake when 
comparing PS-lip to either glycolipid liposome formulation. These results were not 
expected, due to previous knowledge that PS-containing liposomes are avidly 
internalized by macrophages and DCs in vivo.  
 
GM1-lip has prolonged uptake by cells in the LN 
The same liposome batches prepared for the 4 hour in vivo uptake study were 
used for the 24 hour in vivo uptake. Female C57BL/6 mice (n=2 mice per liposome 
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formulation) were subcutaneously injected in the hind flank near the tail base with 250 
nmoles of the indicated liposome formulation. Liposome uptake was monitored by 
fluorescence of OregonGreen488-DHPE lipid incorporated at 1mol% of the liposome 
composition and measured using flow cytometry. As described for the 4 hour in vivo 
uptake study, dendritic cells present in the lymph nodes were selected as staining 
positive for both CD11c and CD11b, as determined by cellular fluorescence; while 
macrophages were classified as having no CD11c staining and high CD11b staining. 
Identified DC and macrophage populations from the same overall LN cell population 
were then plotted for their fluorescence due to liposome internalization 
(OregonGreen488 fluorescence) (Figure 2.7A and 2.7B).  
Surprisingly, uptake of GM1-lip was higher than that of PI-lip in both DC and 
macrophage cell types (p<0.05) (Figure 2.7C and 2.7 D). In comparison to 4-hour 
uptake values, the 24-hour uptake of PI-lip was considerably less in both LN DCs (MFI= 
16.68 ± 0.775) and LN macrophages (MFI= 5.51 ± 0.17) (p<0.01 and p<0.0001 
respectively). Interestingly, GM1-lip exhibited similar uptake by LN DCs at 4 and 24 
hours post injection (MFI= 32.52 ± 5.705 and MFI= 25.31± 3.085, respectively). This 
corresponded with the percentage of LN DCs that contained GM1-lip (4 hour: 18.0% ± 
3.09%; 24 hour: 16.5% ± 3.44%). Together, these results suggest GM1-lip persist in the 
lymphatic system for longer periods of time. Uptake of PS-lip was similar to that of PI-lip 
for both macrophage and DC cell types (Figure 2.7D).  
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DISCUSSION 
In this study we sought to investigate the uptake of two glycolipid-containing 
liposome formulations by macrophages and dendritic cells. Liposomes containing 
10mol% GM1 or PI glycolipid have been previously shown to evade rapid macrophage 
uptake in vitro and in vivo [24, 26, 34, 41]. We hypothesized that these long-circulating 
liposome formulations would reduce the liposomal uptake by macrophages, which in 
turn, may result in increased exposure and uptake by DCs. We have observed that 
10mol% PI-liposomes (1) promote uptake by DCs in vitro and in vivo (2) lose DC-
preferential uptake when ePE:CHEMS composition is used (3) are superior to GM1-lip 
and PEG-lip for enhancing liposomal uptake by DCs. 
In literature, long-circulating liposomes are also referred to as sterically stabilized 
liposomes, glycolipid-bearing liposomes, or Stealth© liposomes. Their main realized 
function is to enhance liposomal delivery of small molecules to tumor after intravenous 
(i.v.) administration, a goal that was only manageable if liposomes could evade rapid 
uptake mediated by macrophages of the spleen and liver (i.e. MPS). Long-circulating 
liposomes have primarily been studied after i.v. injection, as this was the logical route of 
administration for the purpose of tumor-targeted delivery of small molecules. However, 
the applications of long-circulating liposomes may be expanded based on the studies 
presented in this chapter. Since i.v. injection of a vaccine formulation is not ideal for 
multiple reasons, subcutaneous (s.c.) administration of long-circulating liposomes was 
utilized. Subcutaneous administration of liposomes is advantageous for directing 
nanoparticles initially to the draining (local) lymph nodes. Subcutaneous administration 
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of PI- or GM1-containing long-circulating liposomes had not been previously examined 
thus it was unknown whether or not these liposomes would possess the same uptake 
behaviors described after i.v. administration. Since long-circulating liposomes were 
extensively studied in the time before DCs were well defined as potent immune cells, 
the interactions of these liposome formulations with DCs had also not previously been of 
interest to researchers. The concept of reducing rapid liposome uptake by macrophages 
in the MPS with long-circulating liposome formulations introduced decades ago was 
applied to vaccine delivery in this thesis, based on the hypothesis that this reduced 
rapid macrophage uptake may skew some liposome uptake towards DCs. There are 
actually two ideas at play that may lead to enhancing DC uptake of liposomes. One 
possibility is that decreased initial rapid uptake by macrophages using long-circulating 
liposomes may facilitate increased liposome interactions and uptake with DCs. But, 
another possibility is that a liposome formulation may also promote uptake by DCs by a 
more specific interaction with DCs, rather than simply being the result of greater 
liposome availability. These two approaches may stand alone, or the uptake of long-
circulating liposomes may be a result of the combination of the two uptake possibilities. 
In vitro studies using cell lines and primary cells, suggested the use of PI or GM1 
glycolipid in the liposome formulation did not result in reduced liposome uptake 
compared to neutral DOPC:Chol liposomes by the macrophage cell type. However, it 
was realized that including PI glycolipid in the liposome formulation at 10 mol% 
phospholipid could improve liposome uptake by DCs, whereas in macrophages this 
enhancement of liposome uptake was not observed. PI- and GM1-containing liposomes, 
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expected to deter rapid macrophage uptake in vivo based on previously published 
research, were identified in ~60% of macrophage cells in the LN as shown in Figure 
2.6D. Therefore, it appears that PI-liposomes and GM1-lipsoomes injected 
subcutaneously for lymph node targeting may not possess the same ability to deter 
macrophage uptake as described of them following i.v. administration. Although 
macrophage uptake is apparently still a major component of liposome uptake in the LN, 
there is still the possibility to promote DC uptake of liposomes. This would explain how 
PI-liposomes, with initially high macrophage uptake in the LN, still have higher uptake 
than GM1-liposomes in LN DCs. The additional novelty of PI-liposomes is they require 
inexpensive materials, with PI being obtained in abundance from soybean, are easy to 
prepare, and exhibit unique uptake behavior in DCs examined in vitro and in vivo. 
Besides the well-known PEG-coated liposomes, PI-liposomes and GM1-
liposomes represent the most effective formulations for deterring macrophage uptake 
[24, 25, 42]. One explanation for the noticeably reduced macrophage uptake of 
liposomes containing PEG, PI, or GM1 is the so-called shield effect, suggesting the 
bulky, hydrophilic lipid head groups present in these liposome formulations shield the 
lipid’s negative charge from recognition and clearance [21]. It is interesting that the 
bulky hydrophilic coatings present in PEG-lip, PI-lip, and GM1-lip formulations do not 
equally reduce liposome uptake by DCs. PEG-lip and GM1-lip both reduced DC uptake 
of liposomes, while PI-lip did not. The lipid head groups of GM1 and PEG are more 
bulky than PI and would extend further out from the liposome membrane, possibly 
contributing more to the shield effect and resulting in decreased recognition of PEG-lip 
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and GM1-lip by both cell types. However, the less bulky PI lipid head group present in 
PI-lip still exhibits low macrophage uptake, but alternatively increases liposome uptake 
by DCs. These results imply that the shield effect cannot explain the liposome uptake 
differences seen in DCs.  
Surface charge and size of nanoparticles are two important factors affecting 
recognition and uptake by macrophages and dendritic cells. The size of PI-lip and GM1-
lip investigated in this report were equal (≈100nm) and comprised equal anionic 
glycolipid compositions (10mol%). Yet, DC uptake of these liposomes formulations was 
dramatically different. Apparently two of the main determinants of liposome uptake, size 
and surface charge, are not the dominant factors affecting DC-mediated uptake of these 
glycolipid-bearing liposome formulations. Rather, we propose that the lipid head groups 
of these liposomes also determine uptake by DCs.  
The surface density of PI glycolipid plays a role in liposomal uptake by DCs and 
macrophages. While in DCs, 10mol% PI is sufficient to promote uptake, macrophages 
require 50mol% PI to exhibit significant enhancements in liposome uptake. The PI 
density effect on cell uptake has been previously examined in J774 cell lines, therefore 
we had an indication that PI-lip, with increasing PI mol% would increase liposome 
uptake by these cells [24]. However, 10 mol% PI-lip were internalized the same as 
50mol% PI-lip in JAWSII DCs. These results emphasize the different recognition 
mechanism for PI-lip in the two cell types. Whereas J774 macrophages recognize PI-lip 
based on increasing PI surface density (and increasing negative surface charge), 
JAWSII DCs require only the presence of the PI lipid head group at 10mol%. This could 
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be a result of either different binding sites for PI on the two cell lines, or increased PI 
binding sites exist on JAWSII DCs. J774 macrophage uptake of 50mol% PI-lip did 
approach that of 10mol% PI-lip uptake in JAWSII DCs, however this high glycolipid 
content results in accelerated liposome clearance in vivo and would not be a viable 
liposome formulation for deterring macrophage uptake [43].   
 The shield effect explained above has also been used to explain the dramatic 
uptake differences seen between PS-liposomes and either PI- or GM1-liposomes. 
Unlike PI and GM1 lipid head groups, which have a bulky hydrophilic group to shield 
lipid charge, the PS lipid head group exposes the negative charge to the surrounding 
environment. Our results confirm the shield theory in macrophages, however, differential 
DC uptake by PI-lip and GM1-lip formulations require an additional explanation. The role 
of cell-surface receptors has been previously proposed as a method of uptake for 
anionic lipids. Currently, there is no specific PI, GM1 or PS cell-surface receptor that 
has been identified. However, Class B scavenger receptors such as CD36 and SR-BI 
have been indicated as cell-surface receptors of anionic liposomes [44, 45]. In one 
particular in vitro study, 50mol% PI-liposomes and 10-50mol% PS-liposomes competed 
with low-density lipoprotein (LDL) natural ligands of SR-BI and CD36, suggesting these 
receptors recognize anionic liposomes for uptake [44]. SR-BI and CD36 are expressed 
on macrophages and immature dendritic cells and have also been shown to facilitate 
internalization of apoptotic cells in vitro, likely due to binding of PS exposed on the cell’s 
outer lipid membrane [45-47]. The presence of SR-BI and CD36 on DCs could play a 
role in the differential internalization of PI-lip observed in this report. If one, or both, of 
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these scavenger receptors is more highly expressed on the cell surface of DCs, in 
comparison to macrophages, this could explain the observed enhanced uptake of PI-lip 
by only the DCs. Further indirect support of the scavenger receptors’ role in liposomal 
uptake by macrophages can be found in studies performed by Lee et al. These authors 
show J774 macrophage uptake of PS-liposomes is negatively affected by competition 
with polyinosinic acid and polycytidylic acid, both of which are poly-anionic molecules 
known to bind to scavenger receptors [24]. If indeed scavenger receptors are expressed 
by J774 macrophages, they did not appear to play a role in discriminating uptake 
between GM1-lip and PI-lip in these studies. Furthermore, while CD36 and SR-BI are 
involved in the uptake of anionic liposomes and apoptotic cells in vitro, there is no 
evidence to indicate these are the receptors mediating uptake in vivo. In addition, the 
interaction between GM1-lip and either CD36 or SR-BI to our knowledge has not been 
investigated. Therefore it is possible that GM1-lip, another anionic liposome formulation, 
may be recognized by CD36 or SR-BI as well. In conclusion, we cannot exclude the 
possible role that Class B scavenger receptors, CD36 and SR-BI, may have in the 
internalization of the anionic lipids investigated in this report. Although there is also still 
the possibility that other, potentially undiscovered, cell-surface receptors are additionally 
involved. 
The in vivo uptake study confirmed our in vitro finding that PI-lip have increased 
DC uptake compared to GM1-lip. Although, the clear ability of PI-lip to promote DC 
uptake displayed in vitro was weakened in vivo. The uptake of PI-lip by LN 
macrophages was also higher than GM1-lip, signifying that enhanced uptake was not 
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unique to LN DCs. An explanation for the differing in vivo and in vitro results in 
macrophage type cells is that J774 macrophages and the bone marrow-derived 
macrophages used in the in vitro uptake studies are likely not representative of the 
macrophages in the lymph nodes. Although J774 are widely used as representatives of 
macrophage cells, they were originally defined only as ‘macrophage-like’ cells based on 
their many macrophage-like properties including high phagocytic capability, ability to 
bind antibody-coated cells and their adherence in culture [48]. Bone marrow progenitor 
cells exposed only to the growth factor M-CSF, generate a homogenous macrophage 
cell population. Therefore, it is conceivable that lymph node macrophages may 
phenotypically differ from J774 and BMM cells, allowing for identification and increased 
uptake of PI-lip in the LN. The increased recognition observed of PI-containing 
liposomes by LN macrophages conflicts with the many published data demonstrating PI-
containing liposomes reduce uptake by macrophages in the MPS [21, 22, 24, 25, 34]. 
Again, this discrepancy may be a factor of the differing cell types examined. In vivo 
there are many different types of macrophages and DCs, which differ phenotypically 
and functionally [10, 49-53]. As shown, PI-liposomes, understood to deter uptake by 
macrophages located in the spleen and liver of the MPS, appear to have different 
uptake behavior by macrophage cells in the lymph node. The difference in PI-liposome 
uptake exhibited may additionally be a result of LN macrophages being in close 
proximity to high concentrations of liposomes in the LN, facilitating increased binding 
and internalization of PI-lip. Moreover, PI-containing liposomes have continually been 
described as having lesser ability to deter macrophage uptake (in the MPS) when 
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compared to GM1-containing liposomes [21, 24, 33, 34, 43], which may further explain 
the higher uptake of PI-liposomes by LN macrophages. Although the referenced 
publications intravenously administered liposomes and observed this difference 
between PI- and GM1-containing liposomes, the in vivo experiments presented here 
following subcutaneous administration of liposomes, agree with previous data showing 
PI-liposomes are internalized by macrophages more so than GM1-liposomes. 
The uptake of PS-liposomes in vivo is more complex than anticipated. The low 
LN DC and macrophage uptake of PS-lip was attributed to high uptake of these 
liposomes at the site of injection. Oussoren et al. reported that approximately 40% of 
liposomes composed of ePC:Chol:PS (10mol% PS; mean diameter≈70nm) remain at 
the injection site up to 52-hours post injection in rats [30]. Across multiple liposome 
formulations, it was also observed that with increasing mean diameter, more of the 
liposome dose remains at the injection site [30, 54]. Therefore it is plausible that 40% or 
more of the 100nm diameter PS-liposomes used in this study were retained at the 
injection site and not available for uptake by the lymph nodes. Due to the well-known 
remarkably different cell uptake of PI- and GM1-containing liposomes compared to PS-
liposomes, the same uptake behavior at the injection site should not be projected to 
glycolipid-containing, long-circulating liposomes formulations. To add to that point, in a 
separate publication, Oussoren et al. investigated the effect of a liposomal PEG coating 
on liposome uptake from the injection site. It was discovered that liposomes containing 
PEG could increase the amount of liposomes that drained into the lymphatic system 
from the injection site [54]. Since liposomes with a PEG coating, alike PI-lip and GM1-
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lip, are known to have a hydrophilic bulky surface which contributes to their low uptake 
by phagocytic cells, we speculate that PI-lip and GM1-lip may also promote increased 
liposomal drainage from the injection site to the lymphatic system. This may explain why 
PS-lip had lower than expected uptake by the lymph nodes in our in vivo uptake study.  
The low cell fluorescence of LN cells 24 hours after injection could be a result of 
high uptake by cells within a shorter time frame, as well as, the instability of the 
fluorescent lipid marker. Lymphatic uptake of small liposomes (mean diameter≈70nm) 
from the injection site (s.c. injection) is typically completed within 12 hours [29]. After 
lymphatic uptake there is only one opportunity for liposomes to travel through the LNs 
before entering the blood stream. Lymph nodes internalize approximately 1-2% of the 
liposome dose within that one pass through, and more than 50% of that uptake occurs 
within the first 4 hours post injection [29]. The association of liposomes with LN cells 4 
hours post injection was considerably higher than that 24 hours post injection (p<0.05), 
with the exception of GM1-lip uptake by DCs at 4 and 24 hours. This suggests that 
mouse LN cells internalize liposomes within a relatively short amount of time, which is in 
agreement with the timeline discussed above. The low fluorescence of LN DCs and 
macrophages after 24 hours could be a result of the degradation of the fluorescent lipid 
marker used in all studies. OregonGreen488-DHPE, composed of the OregonGreen488 
fluorophore conjugated to the phospholipid DHPE, is an analog of fluorescein that 
overcomes some of the limitations fluorescein possesses. Unlike fluorescein, 
OregonGreen488 is pH-insensitive at physiological pH, with a pKa of 4.7. However, 
internalized liposomes would ultimately expose the fluorophore to a pH<5 in the late 
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stages of the endocytic pathway [55], which would result in a reduced fluorescence. 
Furthermore, the highest cell fluorescence values exhibited after 4-hours uptake is 
associated with the lowest fluorescence values at the 24-hour time point, suggesting 
high initial uptake of liposomes results in reduced readable fluorescence after 24 hours.  
Interestingly, GM1-lip exhibited similar uptake by LN DCs 4 and 24 hours post 
injection. Macrophage uptake of GM1-lip had been significantly reduced from 4 to 24 
hours, however, uptake of GM1-lip was still significantly higher than PI-lip. These results 
imply GM1-lip persist in the lymphatic system and/or lymph nodes for longer periods of 
time, compared to PI-lip. We have shown in this report, and many others have published 
that liposomes containing GM1 are superior to liposomes containing PI at reducing 
macrophage uptake [21, 24, 33, 34, 43]. Therefore, it is probable that GM1-lip had 
improved ability to evade extensive cell uptake initially and be retained in the LN. This 
most likely allowed for GM1-lip to be internalized, albeit at a lower capacity, over an 
extended period of time.  
The pH-sensitive liposome, composed of PE:CHEMS is a valuable delivery 
system that has been studied extensively in our lab for cytosolic delivery [40, 56, 57]. In 
combination with the hemolysin from Lm, LLO, this lipid formulation is especially useful 
as a vaccine carrier to stimulate cell-mediated immunity due to cytosolic delivery of 
antigen [39]. To determine if PE:CHEMS compositions could be applied along with the 
preferential DC uptake exhibited by PI-liposomes, we evaluated the uptake of 
ePE:CHEMS:PI liposomes in macrophages and dendritic cells. Because CHEMS is 
negatively charged at neutral pH, PE:CHEMS liposomes bear a high negative surface 
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charge and were highly internalized by both BMDCs and BMMs. The presence of PI in 
ePE:CHEMS liposomes did not show an advantage in promoting uptake by DCs. 
Remarkably, ePE:CHEMS liposomes containing GM1 (10mol%) retained relatively 
reduced uptake by macrophages compared to PE:CHEMS liposomes. However, GM1 at 
this mol% likely abrogated the pH-sensitivity. Partial pH-sensitivity can be retained with 
low amounts (<5%) of GM1 lipid in a pH-sensitive lipid formulation, although this low 
mol% of GM1 is not sufficient to noticeably improve the circulation times of liposomes 
[23, 58]. Thus, using PE:CHEMS composition was determined to not be suitable in our 
approach to promote liposome uptake specifically by DCs. 
 
CONCLUSION 
 We have investigated the macrophage and DC uptake of two glycolipid-
containing liposome formulations. In vitro studies determined DOPC:Chol liposomes 
containing 10mol% PI glycolipid displayed distinct uptake behavior by DCs, which was 
not seen in macrophages. The presence of 10mol% PI was suitable for promoting 
liposome uptake by DCs whilst having no effect on macrophage uptake. This 
characteristic of 10mol% PI-liposomes was not observed when 10mol% GM1 glycolipid 
was used in the liposome formulation, or when PEG-liposomes were compared. In vivo 
studies determined that the enhanced uptake of PI-liposomes was not DC-specific. PI-
liposomes and GM1-liposomes represent two alternative approaches to enhancing DC 
uptake. In the context of vaccine design, higher initial uptake of PI-liposomes by LN 
macrophages and DCs would increase initial antigen uptake by APCs, which may 
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prompt immune responses. Contrastingly, the lower uptake of GM1-liposomes would 
expose lesser amounts of antigen to cells initially, but this exposure would continue over 
an extended period of time. Based on in vivo results, both PI-lip and GM1-lip 
formulations may be beneficial as vaccine carriers for enhancing antigen delivery to 
DCs. 
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 (C)         (D) 
Figure 2.1 JAWSII dendritic cells exhibit preferential uptake of PI-liposomes 
Liposome uptake by J774 macrophages and JAWSII DCs was assessed using flow 
cytometry. Cells were pulsed with 100μM OregonGreen488 fluorescently labeled 
liposomes for 1 hour at 37°C. Upper panel shows representative histograms of indicated 
groups in (A) J774 macrophages and (B) JAWSII DCs. Lower panel shows mean 
fluorescence intensities (MFI) of (C) J774 macrophages and (D) JAWSII DCs with 
indicated liposome treatment. Data shown represent mean ± SEM, n=3 (**p<0.01, 
***p<0.001, analyzed using one-way ANOVA and Tukey’s post-hoc test). 
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(C)        (D)       
Figure 2.2 Uptake trends in primary bone marrow-derived cells resemble those 
presented in cell lines 
Liposome uptake by BMMs and BMDCs was assessed using flow cytometry. Cells were 
pulsed with 100μM OregonGreen488 fluorescently labeled liposomes for 1 hour at 
37°C. Upper panel shows representative histograms of indicated groups in BMMs (A) 
and BMDCs (B). Lower panel shows mean fluorescence intensities (MFI) of BMMs (C) 
and BMDCs (D) with indicated liposome treatment. Data shown represent mean ± SEM, 
n=2 (*p<0.05, analyzed using one-way ANOVA and Tukey’s post-hoc test). 
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Figure 2.3 Uptake of PEG-lip is comparable to GM1-lip, in BMMs and BMDCs 
Liposome uptake by BMMs and BMDCs was assessed using flow cytometry. Cells were 
pulsed with 100μM OregonGreen488 fluorescently labeled liposomes for 1 hour at 
37°C. Upper panel shows representative histograms of indicated groups in BMMs (A) 
and BMDCs (B). Lower panel shows mean fluorescence intensities (MFI) of BMMs (C) 
and BMDCs (D) with indicated liposome treatment. Data shown represent mean ± SEM, 
n=2 (**p<0.01, ***p<0.001, analyzed using one-way ANOVA and Tukey’s post-hoc test). 
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Figure 2.4 Effect of PI density on the liposome uptake by macrophages and DCs 
Liposome uptake by J774 macrophages and JAWSII DCs was assessed using flow 
cytometry. Cells were pulsed with 100μM OregonGreen488 fluorescently labeled 
liposomes for 1 hour at 37°C. Upper panel shows representative histograms of indicated 
groups in (A) J774 macrophages and (B) JAWSII DCs. (C) Mean fluorescence 
intensities (MFI) of corresponding histograms plotted against increasing PI mol% 
present in the liposome formulation. Data shown represent mean of two independent 
experiments ± SEM 
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Figure 2.5 ePE:CHEMS liposome compositions dissolve liposome uptake trends 
Liposome uptake by BMMs and BMDCs was assessed using flow cytometry. Cells were 
pulsed with 100μM OregonGreen488 fluorescently labeled liposomes for 1 hour at 
37°C. Upper panel shows representative histograms of indicated groups in BMMs (A) 
and BMDCs (B). Lower panel shows mean fluorescence intensities (MFI) of BMMs (C) 
and BMDCs (D) with indicated liposome treatment. Data shown represent mean ± SEM, 
n=3 (**p<0.01, ***p<0.001, analyzed using one-way ANOVA and Tukey’s post-hoc test). 
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Figure 2.6 PI-lip promote uptake by macrophages and DCs present in the LN 
C57BL/6 mice (n=2 per formulation) were subcutaneously injected with 250nmoles of 
the indicated OregonGreen488 fluorescently labeled liposomes in the hind flank near 
the tail base. After 4 hours, inguinal LN cells were stained with fluorescent anti-CD11b 
and anti-CD11c and analyzed by flow cytometry. Upper panel shows histograms of 
indicated groups in (A) CD11b+CD11c- LN macrophages and (B) CD11b+CD11c+ LN 
DCs. (C) Corresponding mean fluorescence intensities (MFI) in cell types. *p<0.05, 
analyzed using one-way ANOVA and Holm-SIdak’s post-hoc test (D) Percentage of 
indicated cells positive for liposomes **p<0.01, analyzed using two-way ANOVA with 
Bonferroni’s post-hoc test. Data shown represent mean ± SEM, n=2 
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Figure 2.7 GM1-lip has prolonged uptake by cells in the LN 
C57BL/6 mice (n=2 per formulation) were subcutaneously injected with 250nmoles of 
the indicated OregonGreen488 fluorescently labeled liposomes in the hind flank near 
the tail base. Twenty-four hours post injection, inguinal LN cells were stained with 
fluorescent anti-CD11b and anti-CD11c and analyzed by flow cytometry. Upper panel 
shows histograms of indicated groups in (A) CD11b+CD11c- LN macrophages and (B) 
CD11b+CD11c+ LN DCs. (C) Corresponding mean fluorescence intensities (MFI) in cell 
types. *p<0.05, analyzed using one-way ANOVA and Holm-SIdak’s post-hoc test (D) 
Percentage of indicated cells positive for liposomes *p<0.05, analyzed using two-way 
ANOVA with Bonferroni’s post-hoc test. Data shown represent mean ± SEM, n=2 
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Liposome 
composition Mole ratio Size* (nm) 
 Poly 
dispersity 
index (PDI) 
Zeta potential 
(mV) 
DOPC:Chol 2:1 111.1 0.190 -4.98 ± -.361 
DOPC:Chol:PI 
(10mol% PI-lip) 9:5:1 105.9 0.104 -9.62 ± -.074 
DOPC:Chol:PI 
(25mol% PI-lip) 7.5:5:2.5 112.4 0.022 -14.1 ± -1.09 
DOPC:Chol:PI 
(50mol% PI-lip) 1:1:1 116.7 0.014 -22.6 ± -1.74 
DOPC:Chol:GM1 
(10mol% GM1-lip) 9:5:1 108.6 0.090 -7.93 ± -.621 
DOPC:Chol:PS 
(10mol% PS-lip) 9:5:1 104.9 0.099 -12.3 ± -0.946 
DOPC:Chol:PS  
(50mol% PS-lip) 1:1:1 109.5 0.107 -26.9 ± -2.07 
DOPC:Chol:PEG-PE 
(PEG-lip) 9:5:1 120.1 0.046 -1.43 ± -0.110 
 
Table 2.1 Composition, size, PDI and zeta potential of liposomes 
Representative particle size, poly dispersity index (PDI) and zeta potential data of 
liposome formulations are shown. Size (diameter; nm) was determined by dynamic light 
scattering and zeta potential was determined by electrophoresis and laser Doppler 
velocimetry. PDI is a dimensionless measure of the width of particle size distribution.  
*Size listed is Z-average particle size 
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Figure 2.8 Lipid structures 
Structures of the predominant species in lipid product 
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CHAPTER 3 
Evaluation of DOPC Liposomes Containing Glycolipid as Vaccine Carriers to 
Stimulate Cell-Mediated Immunity 
 
SUMMARY 
 In Chapter 2, two glycolipid-containing liposome formulations were examined as 
potential vaccine carriers to enhance antigen uptake by dendritic cells (DCs). DCs are 
prime targets for stimulating immune responses from protein vaccine preparations 
because of their unique abilities to stimulate T cells and coordinate innate and adaptive 
immune responses. Liposomes containing phosphatidylinositol (PI) or 
monosialotetrahexosylganglioside (GM1) glycolipid encapsulating the model protein 
antigen ovalbumin (OVA) and the hemolysin listeriolysin-O (LLO) were examined for 
their potential to generate antigen-specific cell-mediated immune responses in 
additional to humoral, antibody responses. Protein subunit vaccines in general have 
failed to generate cell-mediated immunity, especially the activation of CD8+ T cells. 
Therefore, we focused most of our efforts on monitoring the generation of CD8+ T cells 
after immunization with the liposome formulations. Herein we have described glycolipid-
containing dioleoylphosphatidylcoline (DOPC) liposomes encapsulating OVA and LLO 
generated antigen-specific CD8+ T cells after immunization. This is likely a result of 
increased DC uptake of liposomes, especially for PI containing liposomes, as well as
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cytosolic delivery of antigen with the aid of LLO. Liposomes composed of DOPC and PI 
(DOPC:PI liposomes) produced higher mean titers of antigen-specific serum IgG1 and 
IgG2a antibodies compared to DOPC liposomes containing GM1 (DOPC:GM1 
liposomes). However, despite distinctly different uptake by lymph node macrophages 
and DCs, all antigen-specific cell-mediated immune responses monitored were similar 
between the two glycolipid liposome formulations.  
 
INTRODUCTION 
The immune system is categorized into two main responses, innate immunity and 
adaptive immunity. The innate immune system is used to distinguish self from non-self. 
Cells of this immune system recognize unique non-self motifs termed pathogen-
associated molecular patterns (PAMPs) by various pattern-recognition receptors (PRRs) 
on the outside and inside of the cell [1]. Innate immune responses are essential for early 
inhibition of infection and viral/bacterial proliferation. The innate immune system 
functions to produce molecules that stimulate the immune system (e.g., chemokines, 
cytokines and interferons (IFNs)) and activate leukocytes (e.g., macrophages) in 
response to infection [2]. Based on the innate immune system’s determination of non-
self, the adaptive immune response develops antigen-specific immune responses [3]. 
The adaptive immune system is further divided into two arms termed humoral immunity 
and cell-mediated immunity. Humoral immunity is defined by the production of 
antibodies by B lymphocyte cells, which detect pathogens in blood or fluids. Cell-
mediated immunity refers to the activation of CD4+ T helper (Th) cells and CD8+ T 
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lymphocyte cells, also known as cytotoxic T lymphocytes (CTLs). The adaptive immune 
response is also responsible for the generation of antigen-specific memory B and T 
cells. Memory cells are crucial for recognizing re-exposures to a pathogen, facilitating 
quicker host immune responses to infection [4].  
Live attenuated vaccines are extremely effective at preventing infection because 
they elicit strong cellular and humoral immune responses. These strong responses 
mimicked the protective immunity a person would develop in response to a natural 
infection [5]. However, due to safety concerns of live vaccinations, current vaccine 
development has shifted from using live attenuated pathogens to protein subunit 
vaccines. Protein subunit vaccines rely on protein antigens, which inherently have low 
immunogenicity, to generate protective immunity. It is not a surprise then that most of 
these protein subunit vaccines have failed to generate sufficient protective immune 
responses [6, 7]. Specifically, cell-mediated immune responses have been lacking in 
protein subunit vaccines. Cellular immune responses are primarily directed at 
intracellular pathogens, which persist inside host cells protected from antibody 
recognition and opsonization. Many of the most needed vaccines against HIV, cancer, 
hepatitis C and tuberculosis will require cell-mediated responses to clear the infection or 
disease [7-11]. Therefore the development of enhanced cellular responses to protein 
subunit vaccine preparations is an important topic of research. 
A proposed way to stimulate enhanced cell-mediated responses is through 
directing of antigen to the lymph nodes. Lymph nodes (LN) are rich in macrophages and 
dendritic cell (DCs), as well B and T cells [12, 13]. The high density of DCs in close 
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proximity to T cells is why LN targeting is an attractive option for stimulating cell-
mediated immune responses from protein subunit vaccinations. Access to the lymph 
nodes is most importantly dependent on size [14]. Nanoparticle vaccine formulations 
must be small (<0.2 μm) in order to drain into the lymphatic capillaries and travel to the 
lymph nodes [15]. Small liposomes (mean diameter <0.1 μm) can gain access to lymph 
nodes quicker, but they also display higher blood concentrations suggesting they pass 
through the lymphatic system with low uptake by DCs in the lymph nodes [14]. Larger 
nanoparticle formulations may still gain access to the lymph nodes if internalized by 
DCs at the injection site and subsequently migrate to the lymph nodes [14, 15]. Most 
commonly, subcutaneous (s.c.) injection of nanoparticle formulations, including 
liposomes, is used to facilitate delivery to the lymph nodes. The uptake study performed 
with these liposome formulations in Chapter 2 of this thesis, is the only known study to 
characterize the uptake behavior of PI- or GM1-containing liposomes after s.c. 
administration. The use of these liposome formulations has previously been limited to 
small molecule delivery to tumor after intravenous injection.  
From a vaccination standpoint, DCs represent a prime target for stimulating 
robust cellular immune responses towards delivered antigen(s). DCs are unique in their 
ability to “cross-present” antigens to T cells and induce T cell activation in vivo [16-18]. 
Cross-presentation allows exogenously delivered antigen to be loaded on major 
histocompatibility complex (MHC) class I molecules resulting in presentation to CD8+ T 
cells, which are key mediators of cell-mediated immune responses [19, 20]. DCs, unlike 
macrophages, are able to prime naïve CTLs and helper CD4+ T cells using cross-
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presented antigens [16, 17, 21]. Activation of naïve CD4+ and CD8+ T cells, leads to T 
cell proliferation and their transition into effector cells [22, 23]. Two studies carried out 
with DC-deficient mice, have shown DCs are a critical component for antigen cross-
priming to CD8+ T cells as well as protection against the intracellular pathogen Listeria 
monocytogenes (Lm) [16, 24]. One additional study with mice outfitted with mutant DCs 
unable to cross-present antigen observed that mice were severely compromised in their 
ability to generate antigen-specific CD8+ T cells after infection with Lm and concluded 
that DC cross-priming plays an essential role in T cell responses against Lm [25]. 
Targeting material(s) to DCs for uptake can be additionally beneficial since dendritic 
cells that take up antigen or particulate antigen at injection sites can also migrate to 
lymph nodes in order to stimulate T cell responses [26]. This provides material (or 
nanoparticles encapsulating material) access to lymph nodes where effector T and B 
cells reside. DC’s characteristic shape also enables them to interact with multiple T cells 
simultaneously [27]. In vitro it has been estimated that one mature DC can activate 100-
3,000 T cells [28]. In conclusion, increasing antigen delivery to DCs is one approach to 
stimulating more robust immune responses, especially T cell mediated responses.  
 CD8+ T cells are activated by antigen-presenting cells (APCs), such as 
macrophages and DCs, displaying antigen in the context of MHC class I antigen 
presentation [27]. In order to present antigen on MHC I molecules, antigen needs to be 
delivered to the cytosol of cells. To gain access to the cytosol is not an easy feat for 
exogenous antigen. Even formulating antigen into liposomes will still result in 
endocytosis of liposomes and ultimately lead to destruction of delivered components in 
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the lysosome [29]. The hemolysin listeriolysin-O (LLO) from Listeria monocyotgenes 
(Lm) has been used in conjunction with liposomes co-encapsulating antigen to promote 
cytosolic delivery of liposomal antigen. LLO is maximally active at pH~5.5, conditions 
present in the endocytic pathway [30]. Active LLO forms pores in the endosomal 
membrane, thus facilitating the delivery of liposomal antigen to the cytosol of cells. 
However, for effective cytosolic delivery of antigen via LLO, pH-sensitive liposomes are 
generally utilized [29]. pH-sensitive liposomes contain an amphipathic lipid, typically 
phosphatidylethanolamine (PE), which is unable to form stable bilayers at physiological 
pH, and a second stabilizing amphipathic lipid such as cholesteryl hemisuccinate 
(CHEMS) that conditionally stabilizers the bilayer dependent on pH. At physiological pH, 
PE:CHEMS liposomes form stable lipid bilayers. However, at acidic conditions present 
in the endocytic pathway CHEMS loses its negative charge and its therefore unable to 
stabilize the PE lipid bilayer [31]. Thereafter, pH-sensitive liposomes lose their 
membrane integrity, which allows LLO access to the endosomal compartment.  
We had previously examined whether pH-sensitive liposomes could be utilized 
along with the glycolipid-liposome formulations, however the PE:CHEMS compositions 
high negative surface charge resulted in enhanced cell uptake by both macrophages 
and DCs. Liposomes composed of dioleoylphosphatidylcoline (DOPC) with no 
cholesterol (Chol) content to stabilize the membrane are known to lose membrane 
integrity more quickly than their cholesterol-containing counterpart [32, 33]; thus, we 
hypothesized that once internalized and introduced to the acidic endocytic pathway, 
DOPC liposomes would breakdown [34]. Thereafter, LLO would be released into the 
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endosome, as is the case with pH-sensitive liposomes, and antigen could be delivered 
to the cytosol.  
 CD4+ T cells are another component of cell-mediated immunity. These cells are 
activated by APCs that present antigen via MHC class II molecules. MHC class II 
molecules are present in all APCs, including B cells, macrophages and DCs [27]. CD4+ 
cells are known as helper T cells due to their roles in promoting immune responses from 
all cells in the immune system. APCs, B cells and CD8+ T cells all receive direction from 
CD4+ T cells. CD4+ T cells are subdivided into T helper 1 (Th1) and T helper 2 (Th2) 
cells that either enhance or inhibit cell-mediated immunity, respectively [35]. Th1 cells 
promote cell mediated-immunity by secretion of cytokines such as IL-12, TNF-α/β and 
IFN-γ. These cytokines enhance the activation of CTLs and macrophages, and promote 
the differentiation of B cells [35, 36]. B cells that are activated by Th1-type cytokines 
secrete IgG2a, an opsonizing antibody associated with viral clearance. Skewing CD4+ T 
cells to differentiate into Th2 cells results in IL-4, IL-5, and IL-6 production and the 
proliferation of B cells that secrete IgG1, a neutralizing antibody [35, 37, 38]. A Th2 type 
response promotes humoral immunity [36]. 
 
MATERIALS AND METHODS 
Listeriolysin-O (LLO) expression and preparation 
 
The hly gene encoding for LLO was inserted into the bacterial expression 
plasmid pET29b with a polyhistidine tag. Recombinant LLO was purified from E. coli as 
described by Mandal et al. [39], with the following exceptions. Protein expression was 
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induced with 1mM isopropyl β-D-thiogalactopyranoside and grown fro 4-6 hours. After 
which the cell pellet was collected and resuspended in wash buffer (50mM sodium 
phosphate, 300mM sodium chloride, 20mM imidazole, pH 8) containing 2mM PMSF and 
1mM 2-mercaptoethanol and then lysed using a French press. Lysate supernatant was 
incubated with Ni-NTA agarose (Qiagen, Valencia, CA) for 2 hours and the Ni-NTA 
extensively washed with wash buffer. Polyhistidine-tagged LLO was eluted in wash 
buffer containing 400mM imidazole, then extensively dialyzed against HEPES-buffered 
saline containing EDTA (HBSE) (10mM HEPES, 140mM NaCl, 1mM EDTA, pH 8.4) at 
4°C. Protein purity was assessed by SDS-PAGE and activity by hemolysis assay, as 
previously described [39]. Aliquots of LLO were stored at -80°C. 
 
Liposome preparation 
All lipids were obtained through Avanti Polar Lipids (Alabaster, Alabama). 
Liposomes were prepared at a 9:1 molar ratio of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (Δ9-cis) (DOPC)) and one of the following three lipids: L-α-
phosphatidylinositol (Soy) (PI), monosialotetrahexosylganglioside (ovine brain) (GM1), 
or L-α-phosphatidylserine (porcine brain) (PS). This resulted in DOPC liposomes 
containing 10mol% of PI, GM1 or PS. L-α-phosphatidylethanolamine (egg, chicken) 
(ePE) and cholesteryl hemisuccinate (CHEMS) (Sigma-Aldrich) were prepared at a 2:1 
molar ratio. Lipid mixtures were dried completely using a Buchi Rotavapor R-200 rotary 
evaporator to create a lipid film. Lipid films were rehydrated with isotonic (290 ± 10 
mmol/kg osmolality) HBSE, pH 8.4 containing soluble ovalbumin (OVA) (Grade VI, 
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Sigma-Aldrich) at 25 mg/ml (in vivo studies) or 30 mg/ml (in vitro studies) and LLO at 
250 μg/ml (in vivo studies) or 150 μg/ml (in vitro studies). Hydrated lipid films were 
vortexed, subjected to 5 freeze/thaw cycles and sonicated 8x1min cycles using a water 
bath sonicator. Unencapsulated protein was removed by size exclusion chromatography 
using a 1x25cm Sepharose CL-4B column (GE Healthcare). The size of the liposomes 
and zeta potential was determined using a Malvern ZS90 ZEN 3600 zetasizer. 
Phospholipid content of liposomes was quantified using Bartlett’s phosphate assay [40]. 
Determined phospholipid concentrations signified the concentration of liposomes and 
were used in the doing calculations in the antigen presentation assay. GM1 does not 
have a phosphate group and thus the phospholipid assay concentrations determined do 
not include GM1 content of the liposomes; dosing calculations were adjusted to account 
for this. Quantification of encapsulated protein was determined using SDS-PAGE. 
Proteins were resolved on a 4-20% Tris-glycine gel (Invitrogen) with 1X electrode buffer 
(250mM Trizma, 2M glycine) containing 0.1% SDS. Gels were stained with Krypton 
protein stain (Pierce) and protein band intensities were measured on a Typhoon 9200 
(Molecular Dynamics). Protein content was quantified using ImageQuant (GE 
Healthcare). Prepared liposome samples were stored at 4°C and used within 10 days of 
preparation 
 
Cell culture 
All tissue culture media and reagents were purchased from Invitrogen (Carlsbad, 
CA) unless otherwise noted. All cells were maintained in in a humidified incubator at 
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37°C and 5% CO2. B3Z cells, an OVA SIINFEKL peptide-specific CD8+ T-cell 
hybridoma (CD8 OVA, H-2Kb-restricted), were maintained in RPMI-1640 media 
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS), 2mM L-
glutamine, 1mM sodium pyruvate, 100μg/mL streptomycin, 100U/mL penicillin, 50μM 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO), and 25mM HEPES. 
Bone marrow was harvested from femurs and tibia of female C57BL/6 mice and 
differentiated into bone marrow-derived macrophages (BMMs) and bone marrow-
derived dendritic cells (BMDCs). BMM media (DMEM supplemented with 20% HI-FBS, 
30% L-929 cell conditioned media containing macrophage colony stimulating factor (M-
CSF), 2mM glutamine, 100μg/mL streptomycin, 100U/mL penicillin and 55μM 2-
mercaptoethanol) was used to maintain the BMM cultures. BMMs were derived as 
described previously by Stier et al [41]. In short, precursor cells were cultured for 6 days 
in the presence of M-CSF, a component of the L-cell media supplement. Cells were 
replenished with new cell media on day three of culture. BMMs were then harvested on 
day six of culture and stored in liquid nitrogen until needed. BMDC media (RPMI-1640 
supplemented with 10% HI-FBS, 100 μg/mL streptomycin, 100U/mL penicillin, and 
50μM 2-mercaptoethanol) was prepared and murine GM-CSF was added fresh each 
time to the BMDC media at 20ng/ml immediately before use. Cells were cultured in the 
presence of GM-CSF for 6 days, exchanging the cell media every 2 days, after which 
loosely adherent and non-adherent cells were harvested and stored in liquid nitrogen 
until needed.  
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In vitro antigen presentation 
 In vitro antigen presentation was performed as described previously in Andrews 
et al [42]. 2x105 cells/well were added to 96-well plates in serum-containing DMEM the 
night prior. BMM and BMDCs were washed with serum-free DMEM and incubated with 
liposome samples diluted in serum-free DMEM for 2 hours. Cells were dosed based on 
liposomal OVA content, with OVA concentration measuring at 30 μg/ml per well. 
Between all cell washings, the plates were centrifuged at 1500 rpm for 5 minutes to 
reduce cell loss due to washing steps. Cells were washed in serum-containing DMEM 
and incubated for 3 hours. Before fixing, the cells were washed twice in serum-free 
media. Cells were fixed by adding 1% paraformaldehyde in PBS for 15 minutes on ice. 
The 1% paraformaldehyde solution was prepared by dissolving 96% paraformaldehyde 
in warm 1X PBS by drop wise addition of 0.1M NaOH. The solution was pHed to 7 prior 
to fixing cells. Paraformaldehyde was quenched by the addition of excess 0.2 M lysine 
in DMEM for 20 minutes at RT. The cells were washed in serum-containing DMEM 
twice and in B3Z media once after quenching. 2x105 cells/well of B3Z cells in B3Z 
media were added and incubated for 15 hours. Cells were washed with RT 1X PBS, and 
the β-galactosidase substrate (0.15mM chlorophenol red-β-Dgalactopyranoside (CPRG) 
(Calbiochem, Gibbstown, NJ), 100μM 2-mercaptoethanol, 9mM MgCl2, 0.125% NP40 
(Calbiochem, Gibbstown, NJ) in 1X PBS) was added to measure production of 
chlorophenol red by β-galactosidase due to BMM/BMDC antigen presentation of 
SIINFEKL to B3Z cells. The CPRG substrate was incubated with cells for 9 hours, after 
which the absorbance of chlorophenol red was measured at 595 nm on a Synergy plate 
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reader (BioTek, Winooski, VT). BMMs and BMDCs treated with the positive control, 
OVA-CD8 peptide SIINFEKL, consistently had similar chlorophenol absorbance values. 
 
Immunization protocol 
C57BL/6 (7-8 weeks old; Jackson Laboratories, Bar Harbor, ME) were used in 
this study and handled according the University of Michigan Institutional Animal Care 
guidelines. C57BL/6 mice possess the H-2Kb MHC haplotype. Mice were injected 
subcutaneously on each side of the hind flank near the tail base with liposomes 
encapsulating a total of 10μg OVA (1.16-2.89μg LLO) or soluble OVA (10μg) in 100μL 
volume. Naïve mice were injected with the same volume of HEPES buffered saline 
(HBS), pH 8.4. Day 0 mice were injected with prime immunization and on Day 10 
injected with boost immunization. A blood draw was performed before boost injections 
on Day 10 to analyze IgG titers post-prime only. Day 21 mice were euthanized and a 
final blood collection was performed via cardiac puncture. 
 
CD8+ T cell tetramer staining 
 Seven days after Day 0 and Day 10 immunizations, blood was collected from the 
cheeks of mice where the retro-orbital and superficial temporal vein meet as described 
in Golde et al. [43]. K2EDTA coated tubes (BD Biosciences, Franklin, NJ) were used for 
the blood collection. Blood samples were pipetted gently to evenly distribute the cells 
then red blood cells were lysed twice using ACK buffer (Life Technologies). Cells were 
centrifuged at 1500g for 5 min at 4°C between red blood cell lysis steps. Cells were 
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washed with 1X phosphate buffered saline (PBS) containing 1% bovine serum albumin 
(BSA) and centrifuged again. The cell pellet was resuspended with CD16/32 Fc block 
(eBioscience) and incubated for 10 minutes at room temperature (RT) before flow 
cytometry cell staining. A small volume of each sample was removed to establish 
negative and single-color controls. Cells were incubated with T-select H2Kb – OVA 
Tetramer-SIINFEKL-PE (MBL, Japan) for 30 minutes at RT then stained with anti-CD8 
only (prime immunization samples) or additionally with anti-CD44, and anti-CD62L 
(boost immunization samples) for 20 minutes on ice. Cells were washed two times with 
1X PBS/1%BSA and additionally stained with DAPI to distinguish live and dead cells. 
Cell fluorescence was analyzed by flow cytometry and the data was analyzed in FlowJo. 
 
Interferon (IFN)-γ ELISPOT 
The Immunology Core at the University of Michigan Cancer Center prepared the 
enzyme-linked immunospot (ELISPOT) plates used in this assay. ELISPOT plates were 
coated and blocked using a standard ELISPOT protocol. Briefly, plates were coated with 
anti-mouse IFN-γ capture antibody (5 μg/mL) overnight at 4°C followed by washing and 
blocking with serum-containing media. Prepared ELISPOT plates were obtained from 
the Immunology Core on Day 21 of the immunization study. The same day, splenocytes 
from immunized mice were isolated and added to the plates at two densities (5x105 and 
2.5x105 cells/well) and stimulated for 18 hours with either cell media only (in duplicate), 
2.5 μg/mL OVA257-264 peptide (SIINFEKL) (in triplicate) or 1.25 μg/mL concanavalin A (in 
duplicate). Plates were washed two times with PBS and then transferred back to the 
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Immunology Core for completion of the assay and imaging of the plates. In brief, the 
plates were then washed two more times with 1X PBS containing Tween 20 (PBS-
Tween20) then incubated with biotinylated anti-mouse IFN-γ detection antibody at RT. 
Avidin-HRP was added to the wells at RT followed by the addition of the enzyme 
substrate solution (3-amino-9-ethylcarbazole (AEC)). Color development was stopped 
by washing with distilled water. The plates were dried completely at RT after which the 
number of spot-forming units (SFU) in each well was determined using a computerized 
CTL ImmunoSpot Image Analyzer. 
 
Anti-OVA IgG1 and IgG2a ELISA 
 Blood samples were collected on Day 10 and Day 21 in microtainer tubes with 
serum separator (BD Biosciences, Franklin, NJ). Sera were collected after centrifuging 
the blood samples at 10000xg for 5 minutes. Sera were used immediately or stored at -
80°C until needed. Maxisorp NUNC plates were coated with 10 μg/mL OVA in 0.1M 
sodium phosphate, pH 9.0 buffer overnight at 4°C. Plates were washed 6x with PBST 
(1x phosphate buffered saline, 0.05% Tween) before adding 1X PBS/1%BSA blocking 
buffer. Plates were blocked for a minimum of 2 hours at RT or overnight at 4°C. The 
plates were washed 6x with PBST and incubated with serial dilutions of sera (in 
duplicate) in 1X PBS/1% BSA/0.05% Tween 20 dilution buffer overnight at 4°C. Anti-
OVA isotype-specific secondary antibodies (goat anti-mouse IgG2a-biotin conjugated or 
goat anti-mouse IgG1-biotin conjugated) (Southern Biotech, Birmingham, AL) were 
detected with Avidin-HRP (eBioscience, San Diego, CA). Plates were developed with 
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TMB substrate (KPL, Gaithersburg, MD) and color development was stopped with the 
addition of 2N sulfuric acid. Absorbance was read at 450nm on a Synergy plate reader 
(BioTek, Winooski, VT) and the data were fit to a 4-parameter curve on the Gen5 data 
analysis software (Biotek, Winooski, VT). Titer was defined as the reciprocal of the 
highest dilution where absorbance read above the mean absorbance + 3 standard 
deviations of the negative control sera (naïve mice sera).  
 
RESULTS 
DOPC:PI and DOPC:GM1 liposomes encapsulating OVA and LLO can deliver OVA 
to the cytosol of BMMs and BMDCs  
 Liposomes composed of DOPC and glycolipid were formulated with LLO and the 
model antigen ovalbumin (OVA) and evaluated for their ability to deliver OVA to the 
cytosol of cells. For LLO to be active, the liposomes must break down sufficiently 
enough for LLO to be released into the endosome. Thereafter, LLO facilitates the 
formation of pores in the endosomal membrane, allowing for cytosolic delivery of OVA. 
Although these DOPC-glycolipid liposomes are not pH-triggered to deform, as some pH-
sensitive liposome formulations are, these liposomes are, apparently, still able to 
release LLO into the endosome for action. Antigen presentation is monitored by the 
substrate conversion to chlorophenol red, which is mediated by B3Z T cells activated via 
MHC Class I antigen presentation of the OVA CD8 peptide, SIINFEKL (Figure 3.1). This 
assay is specific for MHC Class I antigen presentation, however, it does not discern 
between antigen delivered via LLO to the cytosol from cross-presented exogenous 
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antigen on MHC I molecules. The glycolipid incorporated in the liposome formulation did 
not affect the cytosolic delivery of OVA, as both DOPC:PI and DOPC:GM1 liposomes 
resulted in similar antigen presentation by bone marrow-derived macrophages (BMMs) 
and bone marrow-derived dendritic cells (BMDCs). 
 
Glycolipid liposome formulations generate OVA-specific CD8+ T cells and 
CD44+/CD62L+ memory CD8+ T cells in immunized mice 
 C57BL/6 mice were immunized via subcutaneous injection on Day 0 and Day 10 
with 10 μg OVA in soluble or liposomal formulations (Figure 3.2). Table 3.1 displays 
physical characteristics of the liposome vaccine formulations. An MHC tetramer assay 
was used to detect and quantify antigen-specific CD8+ T cells generated as a result of 
immunizations. MHC-I-SIINFEKL tetramers bind to CD8+ T cells displaying the specific 
matching T cell receptor for SIINFEKL. Cells collected from the blood of immunized 
mice were stained with fluorescent MHC-I-SIINKEFL tetramers and fluorescent cell 
markers (i.e. anti-CD8, anti-CD44, anti-CD62L) then analyzed by flow cytometry. 
Peripheral blood mononuclear cells (PBMCs) isolated from the blood of immunized mice 
were monitored for OVA-specific CD8+ T cells on Day 7 (7 days post-prime) and Day 17 
(7 days post-boost), in addition to OVA-specific CD44+/CD62L+ memory CD8+ T cells on 
Day 17 (Figure 3.3A and 3.3B). 
Seven days post prime immunization, the mean percentage of OVA-specific 
CD8+ T cells was 0.49% ± 0.03% for DOPC:PI  liposomes and 0.29% ± 0.02% for 
DOPC:GM1 liposomes. Both DOPC:PI and DOPC:GM1 liposome formulations 
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generated higher percentages of CD8+ T cells compared to soluble OVA (0.145% ± 
0.01%) (p<0.01 and p<0.05, respectively). Comparing glycolipid liposome formulations, 
DOPC:PI liposomes produced a statically significant higher frequency of antigen specific 
CD8+ T cells compared to DOPC:GM1 liposomes (p<0.01) (Figure 3.3A). In addition to 
our glycolipid liposome formulations, we also immunized mice with pH-sensitive 
ePE:CHEMS liposomes (n=4 mice), a liposome formulation well studied for cytosolic 
antigen delivery. ePE:CHEMS liposomes generated 1.00% ± 0.25% of OVA-specific 
CD8+ T cells (data not shown).  
Boost immunizations with soluble OVA did not alter the percentage of antigen-
specific CD8+ T cells (prime: 0.145% ± 0.01%; boost: 0.165% ± 0.01%). However, boost 
immunizations with liposome formulations did improve antigen-specific CD8+ T cell 
frequency.  CD8+ T cell frequencies after boost were 2.22% ± 0.93% for mice 
immunized DOPC:GM1 formulations and 3.96% ± 1.05% for DOPC:PI formulations 
(Figure 3.3A). There is an obvious trend of increasing mean% of CD8+ T cells in the 
order of soluble OVA<DOPC:GM1<DOPC:PI. However, the reported CD8+ T cell 
frequencies from soluble OVA, DOPC:PI or DOPC:GM1 immunized mice were not 
considered to be statistically different from one another (ANOVA p=0.09), which is due 
to the inter-subject variance of mice immunized with the liposome formulations. Mice 
immunized with ePE:CHEMS liposomes also exhibited variable T cell frequency with an 
observed mean percentage of 4.57% ± 1.29% (data not shown). Remarkably, 
immunization with DOPC:PI and DOPC:GM1 liposome formulations generate a similar 
percentage of OVA-specific CD8+ T cells when compared to the ePE:CHEMS liposome 
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formulation, the latter being specifically designed for cytosolic delivery of encapsulated 
material for presentation to CD8+ T cells. Overall the data indicate DOPC:PI and 
DOPC:GM1 liposomes can improve antigen-specific CD8+ T cell frequency in mice, 
indicating both liposome formulations promote adaptive, cell-mediated immune 
responses. 
On Day 17, antigen-specific CD8+ T cells obtained from the blood of mice were 
additionally probed for CD44+ and CD62L+, indicators of memory cells developed from 
the expanded CD8+ T cell population.  Immunization with PI- or GM1- containing 
liposome formulations generated memory T cells in equal quantities (Figure 3.3B). 
Encapsulating OVA inside DOPC:PI or DOPC:GM1 liposomes co-encapsulating LLO, 
stimulated significant enhancements in memory T cell generation compared to 
immunization with only soluble OVA antigen (p<0.05). Immunizations with soluble OVA 
developed some antigen-specific memory T cells, although, this amount was not 
considered to be statistically different compared to mice that received no OVA antigen 
(naïve).  
 
Immunization with DOPC:PI or DOPC:GM1 liposomes produce similar numbers of 
OVA-specific IFN-γ secreting cells 
 An ELISPOT assay was performed to quantify the antigen-specific IFN-γ 
producing cells. Monitoring the number of cells secreting IFN-γ in response to CD8 
peptide stimulation gives an indication of the CD8+ T cell response generated by 
immunization. Cells were plated in triplicate, at two cell densities, to assess spot 
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formation after OVA-CD8 peptide (SIINFEKL) stimulation. The data shown in Figure 3.4 
are the results of the higher cell density wells, although the results at the lower cell 
density were in agreement. The average number of spots formed per 1x106 cells was 
143.5 ± 26.86 and 138.5 ± 26.99 for mice immunized with DOPC:PI liposomes and 
DOPC:GM1 liposomes, respectively. ePE:CHEMS liposomes produced similar numbers 
of IFN-γ producing cells with mean spots formed equaling 145.2 ± 27.87 (data not 
shown). Mice immunized with soluble OVA produced spots (SFU≤5) at the same level 
as background (naïve mice). These results confirm the expansion of antigen-specific 
CD8+ T cells as a result of liposomal immunizations we reported using MHC I tetramer 
staining and additionally indicate that the T cells generated produce IFN-γ in response 
to OVA peptide re-stimulation to aid the cellular immune response. 
 
DOPC:PI liposomes improve Anti-OVA IgG1 and IgG2a titers 
 Antibody titers are an important measure of humoral protection provided by 
immunization(s). Moreover, the antibody subclasses produced can indicate Th immune 
responses, where IgG1 is associated with a Th2 response and IgG2a associated with a 
Th1 response. Sera collected on Day 10 and Day 21 from immunized mice were 
analyzed for IgG1 and IgG2a by ELISA. After prime immunizations only, no significant 
differences between the liposome formulations existed, but overall, immunizations 
induced primarily IgG1 with lower IgG2a titers. The respective ratios of anti-OVA 
IgG1/IgG2a was 8.9 and 13.8 for DOPC:PI and DOPC:GM1 liposomes (data not 
shown). After boost immunization, antibody titers indicate mice immunized with 
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DOPC:PI liposomes evoke a stronger antibody response in comparison to DOPC:GM1 
liposomes, with higher mean titers of anti-OVA IgG1 and IgG2a antibodies (p<0.01) 
(Figure 3.5). We corroborated previous data from our lab indicating ePE:CHEMS 
liposomes induce high IgG1 titers with low IgG2a titers; in this study we determined the 
IgG1/IgG2a ratio after ePE:CHEMS boost immunization was 10 (data not shown). Both 
glycolipid liposome formulations improved that IgG1/IgG2a ratio to 3.3 indicating these 
formulations can promote Th1 immunity. While immunization with ePE:CHEMS 
liposomes produced similar antigen-specific serum IgG1 titers as the glycolipid liposome 
formulations (p>0.05), the serum IgG2a titers were lower than those produced from 
immunizations with PI-lip (p<0.0001) and GM1-lip (p<0.05). Immunization with soluble 
OVA produced no detectable titers after prime or boost immunizations at the lowest 
tested dilutions.  
 
DISSCUSION 
 Stimulating cell-mediated immunity via protein subunit vaccine formulations is 
challenging due to the low immunogenicity of soluble protein antigens. Encapsulating 
soluble protein antigen in liposomes can protect the antigen from degradation and also 
deliver antigen to cells of the immune system, specifically APCs. We sought to compare 
glycolipid-containing liposomes for their ability to stimulate immune responses with 
focus on the cell-mediate immune response. Liposomes composed of DOPC 
phospholipid and either PI or GM1 glycolipid encapsulating OVA and LLO were found to 
(1) deliver OVA to the cytosol of macrophages and DCs for MHC class I antigen 
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presentation to T cells (2) generate antigen-specific CD8+ T cells and memory T cells in 
vivo (3) stimulate B cell production of anti-OVA IgG1 and IgG2a antibodies. The 
glycolipid formulations generated similar immune responses for all those that were 
monitored, with the exception that liposomes containing PI glycolipid produced the 
highest titers of IgG1 and IgG2a. We also show that immunization with soluble OVA 
alone does not stimulate CD8+ T cell responses, in alignment with general conclusion 
that exogenous soluble protein alone is not able to enter the cytosol of cells, or be 
cross-presented by DCs in vivo [19, 44]. 
 The studies herein establish DOPC:PI and DOPC:GM1 formulations as viable 
vaccine delivery formulations to promote antigen-specific immune responses. Our 
results indicate DOPC:PI and DOPC:GM1 liposomes are capable of stimulating cell-
mediated immune responses in addition to antibody responses after vaccination. 
Furthermore, antibody responses generated after vaccination with DOPC:PI or 
DOPC:GM1 liposome formulations included IgG2a antibodies, which indicates Th1 type 
immunity that further promote cell-mediated responses. In comparison to ePE:CHEMS 
immunized mice, which are known to produce primarily high anti-OVA IgG1 titers 
(dominant Th2 immunity), DOPC:PI and DOPC:GM1 immunized mice had significantly 
increased IgG2a antibodies, further demonstrating that the glycolipid-containing 
liposome vaccine formulations examined promote Th1 immunity.  
 CD8+ T cell tetramer staining and ELISPOT monitoring of IFN-γ producing cells 
show DOPC:PI and DOPC:GM1 liposomes generate similar numbers of antigen-specific 
CD8+ T cells after prime-boost vaccination. Following boost injections, the T cell MHC 
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tetramer staining was more variable between subjects, which prevented statistically 
significant conclusions from being drawn. Tetramer staining post-boost immunization 
with DOPC:GM1 liposomes indicated two high responders and 3 low responders, with 
minimal variability within the two groups. However, the underlying reasoning as to why 
DOPC:GM1 immunizations produced high and low responses could not be related to the 
formulation of the liposomes or the administration of the immunizations, and therefore is 
presently unclear. It is worthwhile to note that liposomes containing GM1 have 
constantly produced more variable results in vivo and in vitro. ELISPOT analysis of IFN-
γ producing cells was additionally performed as a separate measure of T cell activation. 
In vivo, CD8+ T cells will secrete IFN-γ, a cytokine that promotes Th1 immunity and cell-
mediated responses. The ELISPOT results align with CD8+ T cell tetramer staining, 
indicating DOPC:PI and DOPC:GM1 formulations equally generate antigen-specific 
CD8+ T cells.  
PE:CHEMS liposomes encapsulating OVA and LLO have been previously shown 
to generate antigen-specific CD8+ CTL responses [29, 39]. We report that pH sensitive, 
ePE:CHEMS liposomes show no advantage compared to DOPC:PI and DOPC:GM1 
liposomes in stimulating CD8+ T cell responses. This could be a result of DOPC:PI and 
DOPC:GM1 having increased antigen delivery to DCs, similar capability of intracellular 
delivery of antigen, or a combination of both characteristics both of which are further 
discussed below. 
pH-sensitive PE:CHEMS liposomes containing LLO are remarkably more efficient 
at delivering macromolecules into the cytosol of cells compared to non-pH-sensitive 
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formulations [29, 45]. Therefore the ability of DOPC:PI and DOPC:GM1 liposomes to 
produce equal amounts of CD8+ T cells as ePE:CHEMS liposomes is an interesting 
observation. Liposomes composed of purely ePC or DOPC lipids exist in a fluid 
membrane state and have been reported to leak liposomal contents within short periods 
of time in buffer or plasma [32, 33, 46]. While the addition of glycolipid to the DOPC 
liposome composition stabilized the liposome formulation at physiological pH [32, 47], 
these PC liposomes would lose membrane integrity in the acidic endocytic pathway [34]. 
Similarly, bilayer destabilization due to acidifying pH is how ePE:CHEMS liposomes 
release their encapsulated contents [31]. Liposomes composed of DOPC:PI or 
DOPC:GM1 have not previously been evaluated for their cytosolic delivery of antigen. 
However we have performed in vitro antigen presentation experiments that indicated 
DOPC:PI and DOPC:GM1 liposomes encapsulating LLO and OVA result in OVA 
presentation to CD8+ T cells, while DOPC:Chol:PI and DOPC:Chol:GM1 containing LLO 
and OVA liposomes do not (data not shown). Previous studies that have reported 
PE:CHEMS enhances cytosolic delivery compared to non-pH-sensitive liposomes made 
this observation when comparing to DOPC:CHEMS non-pH-sensitive liposomes [29, 
34]. In the DOPC:CHEMS liposome formulation, CHEMS still acts as a bilayer stabilizer 
especially at the high % of liposome composition used. Based on these studies and the 
in vitro antigen presentation studies mentioned, it is reasonable to assume that the 
addition of a stabilizer such as cholesterol or CHEMS impairs the ability of DOPC 
liposomes to deliver antigen into the cytosol. The addition of glycolipid to stabilize 
DOPC liposomes used here may have had a slight negative effect on ability for cytosolic 
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delivery, however the effect would presumably be less drastic than cholesterol or 
CHEMS addition to DOPC liposomes because glycolipid was present at 10mol% 
phospholipid (or 6.6% total lipid), whereas cholesterol or CHEMS typically comprises 
30% or more of total lipid content. Therefore the DOPC:PI and DOPC:GM1 liposomes 
used in this report may facilitate lipid membrane disruption in the acidifying endosome, 
similar to pH-sensitive ePE:CHEMS formulation.  
The hemolysin LLO component of these liposomal vaccine formulations may 
have also played a role in the immune responses monitored in this immunization study. 
The usage of LLO in liposome formulations was primarily to induce cytosolic delivery of 
antigen, however, LLO has also been realized to have adjuvant-like effects. The 
inherent ability of LLO to disrupt endosomal membrane bilayers is cause for alarm in 
infected cells and this causes a multitude of cellular responses after exposure to LLO 
[48, 49]. Cell exposure to LLO-expressing bacteria or exogenously added LLO, results 
in numerous cell-signaling events including those that trigger T cell and DC death [50, 
51], production of pro-inflammatory cytokines IL-1 and IFN-γ by DCs and macrophages 
[52-54], and phosphorylation of MAP kinases in HeLa cells, which plays roles in 
cytokine responses and cell proliferation [49, 55]. LLO has been shown to have an 
adjuvant effect, stimulating pro-inflammatory cytokine production from APCs and 
resulting in decreased tumor volume, when either fused to or co-injected with HPV-16 
E7 protein [56]. Therefore it is probable we also observed an adjuvant effect due to the 
LLO protein component in the liposomal vaccine formulations examined. 
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We have previously described that DOPC liposomes containing PI and GM1 are 
internalized by DCs in vivo, with initially enhanced DC uptake using PI lipid, and lower 
yet extended uptake of liposomes bearing GM1 lipid. Although we have not directly 
compared the in vivo DC uptake of these glycolipid formulations with ePE:CHEMS 
liposomes, the latter show predominantly high uptake by macrophages with lesser 
ability to enhance DC uptake in vitro (Chapter 2, Figure 2.5). Therefore, increased 
antigen delivery to DCs using glycolipid-containing liposome formulations may have 
stimulated enhanced CD8+ T cell responses based on DCs’ unique abilities to cross 
present antigen and activate naïve T cells. Interestingly, Collins et al. has described a 
non-pH-sensitive liposome composed of DOPC and dioleoylphosphatidylserine (DOPS), 
DOPS being another anionic lipid, which generated MHC Class I restricted T cell 
responses to OVA delivery in vivo [57]. In addition, these authors did not see this 
response in vitro when using macrophages. The MHC Class I OVA response observed 
was inferred to be a result of DC cross-presentation in vivo. These results additionally 
demonstrate how it may be possible for DOPC:PI and DOPC:GM1 liposomes to 
generate antigen-specific CD8+ T cells as a result of internalization by DCs.  
In relation to our in vivo uptake study previously discussed in Chapter 2, it 
appears that the immunological outcomes measured here are not drastically affected by 
the differences in glycolipid-liposome uptake we observed by lymph node cells. The 
initially enhanced macrophage and DC uptake we saw of PI- liposomes nor the more 
extended macrophage and DC uptake observed of GM1-liposomes resulted in 
significantly enhanced antigen-specific CD8+ T cells generated from prime-boost 
	 106	
vaccinations. The only advantage of immunization with DOPC:PI liposomes was the 
increased anti-OVA IgG1 and IgG2a antibody titers.  
 
CONCLUSION 
We clearly show that soluble OVA co-encapsulated with LLO inside DOPC:PI or 
DOPC:GM1 liposomes are capable of producing CD8+ T cells, a measure of cell-
mediated immunity. DOPC:PI and DOPC:GM1 liposomes generated similar CD8+ T cell 
frequencies and T cell functionality. DOPC:PI and DOPC:GM1 liposome formulations 
stimulate B cell production of IgG2a, a sign of Th1 immunity induced by vaccination. In 
addition, the glycolipid vaccine formulations did not negatively effect the production of 
anti-OVA IgG1. These glycolipid vaccine carriers show promise even when compared to 
ePE:CHEMS liposomes, a liposome formulation designed to deliver antigen to the 
cytosol for increased CD8+ T cell responses.  
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Liposome 
composition Mole ratio Size (nm) PDI 
Zeta potential 
(mV) 
ePE:CHEMS 2:1 164.7 0.235 -21.1 ± -1.614 
DOPC:PI 9:1 162.8 0.281 -10.4 ± -.8001 
DOPC:GM1 9:1 170.8 0.296 -10.5 ± -.8084 
 
 
Table 3.1 Summary of representative size, PDI and zeta potential of liposomes 
The particle size, poly dispersity index (PDI) and zeta potential of liposomes were 
determined after sonication. Size (diameter) was determined by dynamic light scattering 
and zeta potential was determined by electrophoresis and laser Doppler velocimetry. 
PDI is a dimensionless measure of the width of particle size distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 108	
  
 
Figure 3.1 DOPC:PI and DOPC:GM1 liposomes encapsulating OVA and LLO can 
deliver antigen to the cytosol of BMMs and BMDCs 
BMMs and BMDCs were plated in equal numbers one day prior to the addition of 
liposomes. DOPC:PI or DOPC:GM1 liposomes encapsulating OVA and LLO were 
administed to cells while matching the OVA dose at 6 μg/well. Cells were incubated with  
liposomes for 2 hours. After which, liposomes were washed off and cells were further 
incubated for 3 hours and the fixed. B3Z cells, a T cell hybridoma recognizing MHC I-
SIINFEKL complexes in the context of H2kb, were added to fixed cells for 15 hours. The 
antigen presentation of BMMs and BMDCs to B3Z T cells was monitored by the 
conversion of CPRG substrate to chlorophenol red in the activated B3Z cells and 
measured by absorbance at 595nm. Data shown represent mean ± SEM, n=3. Two-way 
ANOVA detected no significant differences in antigen presentation (p=0.06). 
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Figure 3.2 Flowchart for immunization study 
 
 
 
 
Day 0
•  Prime injection
•  10 μg OVA
•  Treatment groups
•  DOPC:PI (5 mice)
•  DOPC:GM1 (5 mice)
•  ePE:CHEMS (4 mice)
•  Soluble OVA (2 mice)
•  Naive (HBS) (2 mice)
Day 7
•  Collect blood for CD8+ T cell tetramer staining
Day 10
•  Collect blood for Anti-OVA IgG titers
•  Boost injection 
•  10 μg OVA
•  Same groups as above
Day 17
•  Collect blood for CD8+ T cell tetramer staining and 
Memory T cell tetramer staining
Day 21
•  Euthanize mice
•  Collect blood for Anti-OVA IgG titers
•  Harvest spleen for ELISPOT of Ag-specific IFN-γ	
secreting cells
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(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Glycolipid liposome formulations generate OVA-specific CD8+ T cells 
and CD44+/CD62L+ memory CD8+ T cells in immunized mice 
Female C57BL/6 mice were injected subcutaneously with 10μg OVA in liposome or 
soluble formulations on Days 0 and 10. LLO in the liposome formulations ranged from 
1.16-2.35μg (prime) and 1.89-2.89μg (boost). The percentage of antigen-specific CD8+ 
T cells was determined by flow cytometry analysis seven days post injections. PBMCs 
in the blood were evaluated for OVA-specific CD8+ T cells by staining with fluorescent 
SIINFEKL-MHC tetramers. (A) Percentage of OVA-specific CD8+ T cells after prime and 
boost immunizations. Data shown represent mean ± SEM, n=2-5 mice/group (B) 
Percentage of OVA-specific CD8+ memory T cells after boost immunization. Data shown 
represent mean ± SEM, n=2-5 mice/group (*p<0.05, **p<0.01 analyzed by one-way 
ANOVA and Tukey’s post-hoc test). 
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Figure 3.4 Immunization with DOPC:PI or DOPC:GM1 liposomes produce similar 
numbers of OVA-specific IFN-γ secreting cells 
Female C57BL/6 mice were injected subcutaneously with 10μg OVA in liposome or 
soluble formulations on Days 0 and 10. LLO in the liposome formulations ranged from 
1.16-2.35μg (prime) and 1.89-2.89μg (boost). Day 21, mice were sacrificed and 
splenocytes analyzed for OVA-specific IFN-γ producing cells via ELISPOT. Splenocytes 
were stimulated with 2.5 μg/ml SIINFEKL (OVA-CD8 peptide) or cell media only for 18 
hours. As a positive control, cells were also incubated with Con A, a non-specific 
stimulant, for 18 hours. There was no statistical difference between the numbers of 
spots formed when cells were stimulated with ConA. Data shown represent the mean 
number of IFN-γ spot forming units (SFU) ± SEM, n=2-5 mice/group. Analyzed by two-
way ANOVA and Tukey’s post-hoc test. 
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Figure 3.5 DOPC:PI liposomes improve Anti-OVA IgG1 and IgG2a titers 
Female C57BL/6 mice were injected subcutaneously with 10μg OVA in liposome or 
soluble formulations on Days 0 and 10. LLO in the liposome formulations ranged from 
1.16-2.35μg (prime) and 1.89-2.89μg (boost). Mice were sacrificed on Day 21 to 
analyze anti-OVA IgG titers. Sera collected from the blood of immunized mice were 
analyzed by ELISA for OVA-specific IgG1 and IgG2a antibodies. Mice immunized with 
soluble OVA did not read above background at the lowest dilution tested and the data 
are not displayed. Data shown represent the log transformation of antibody titers ± 
SEM, n=5 mice/group. (**p<0.01 analyzed by one-way ANOVA and Tukey’s post-hoc 
test). 
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CHAPTER 4 
Significance and Future Directions 
 
SIGNIFICANCE 
 This thesis presents the first known study to investigate the uptake of liposomes 
containing either phosphatidylinositol (PI) or monosialotetrahexyosylganglioside (GM1) 
glycolipid by dendritic cells, and further compare this uptake to that by macrophages. 
The two liposome formulations considered in this thesis have previously been realized 
to reduce liposome uptake by macrophages in the mononuclear phagocyte system 
(MPS) after intravenous (i.v.) injection of the liposome formulation [1, 2]. The only 
recognized purpose of these liposome formulations was delivery of small molecules to 
peripheral tissues (i.e. tumor) after i.v. injection [3, 4]. The uptake of these liposome 
formulations after subcutaneous administration had not been previously examined. This 
thesis also serves as the first known body of work that describes PI- or GM1-containing 
long-circulating liposomes as vaccine delivery vehicles, specifically after subcutaneous 
administration.  
Macrophage clearance is generally accepted as the main route of liposomal 
clearance from the body. Even long-circulating liposomes, such as PI-liposomes GM1-
liposomes and PEG-coated liposomes will eventually be cleared by macrophages in 
mice [5-7]. This research was stimulated by the notion that the decreased initial 
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macrophage uptake described for PI or GM1-containing liposome formulations may 
facilitate increased interactions with and uptake of these liposomes by another major 
phagocytic cell type, dendritic cells (DCs). The use of a DC-targeting ligand or DC-
specific antibody conjugated to the liposomal membrane is typically required to augment 
liposomal uptake by DCs. However, we have shown that incorporating PI glycolipid in 
the liposome composition can promote liposomal uptake by DCs. We also have 
demonstrated that liposomes containing 10mol% PI have enhanced uptake by DCs in 
comparison to liposomes containing 10mol% GM1, while macrophage uptake of these 
two liposome formulations were similar. These are important observations, which show 
that complex targeting approaches may not be necessary when seeking improved DC 
uptake of a lipid nanoparticle formulation. With trends in vaccine research and 
development delving into more complex approaches in an effort to stimulate greater 
immune responses, this research suggests that complexity may not always be 
warranted. It may be possible to stimulate necessary immune responses just by 
directing nanoparticles to lymph nodes, areas rich in immune cells. 
Previous uses of glycolipid- containing long-circulating liposome formulations 
focused on small molecule drug delivery to peripheral tissues after intravenous 
administration [4, 8]. Intravenous injections are not an ideal route of administration for 
vaccinations, therefore subcutaneous injection was the route of administration chosen in 
in vivo studies. The liposome formulations of primary interest in this thesis had not 
previously been administered subcutaneously and thus, the results presented are the 
first to describe their uptake behaviors after subcutaneous administration. We show that 
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subcutaneous administration of liposomes could result in uptake by draining lymph node 
(LN) cells, which provides the generation of significant CD8+ T cell responses. These PI- 
or GM1- glycolipid liposome formulations were initially of interest as vaccine carriers 
because of their ability to deter initial macrophage uptake and potentially increase 
liposomal antigen delivery to DCs. The targeting of DCs may promote enhanced 
immune responses from the delivered protein antigen [9-12]. We predicted that the 
higher DC uptake observed with PI-containing liposomes would augment cell-mediated 
immune responses when this liposome formulation was utilized as a vaccine carrier. 
However, it appears that this enhanced DC uptake had little effect on the cell-mediated 
immune responses generated. Still, both PI-containing liposomes and GM1-containing 
liposomes were considered effective vaccine carriers for stimulating cell-mediated 
immune responses from the protein antigen. This is true even when the glycolipid 
liposome formulations were compared to ePE:CHEMS liposomes, a liposome 
formulation designed to deliver encapsulated material to the cytosol for increased CD8+ 
T cell responses.  
We have also demonstrated that glycolipid-containing liposomes formulated 
without cholesterol and encapsulating the hemolysin, listeriolysin-O (LLO), can be used 
to deliver the protein antigen ovalbumin (OVA) into the cytosol of macrophage and 
dendritic cells. Liposomes are most typically formulated with cholesterol in order to 
stabilize the lipid membrane. In some cases, however, stabilizing the liposome may 
thwart liposomal delivery of encapsulated material to cells. The studies presented in this 
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thesis exemplify the idea that simple manipulations of liposome compositions can 
produce significant effects on liposome uptake and liposomal delivery. 
 
FUTURE DIRECTIONS 
 The glycolipid liposome formulations presented have shown promise as vaccine 
delivery systems that generate cell-mediated immune responses from protein antigen 
delivery. Further development of these liposome formulations as vaccine carriers should 
include the use of an adjuvant for enhanced cell-mediated immune responses [13]. The 
molecular adjuvant consisting of CpG oligodeoxyribonucleotides (ODNs) contains 
unmethylated CpG sequences that mimic bacterial DNA. These sequences are 
recognized by TLR9, a pattern-recognition receptor (PRR) located in endosomes [14]. 
The location of TLR9 is fitting for liposomal delivery of encapsulated cargo into the 
endosome. CpG-ODNs have been characterized as an adjuvant in multicomponent 
liposomal formulations previously and were shown to induce robust Th1 immunity 
(promoted by CD4+ Th1 T cells) and CD8+ cell-mediated immune responses [15]. 
Alternatively, another experimental adjuvant, poly(I:C), a synthetic double stand RNA 
resembling viral material, could be used to skew Th1 responses. Poly(I:C) is recognized 
by multiple PRRs, including TLR3 in the endosome, and RIG-I and MDA-5 in the cytosol 
of cells. Recognition of poly(I:C) in the endosome or cytosol results in the production of 
type I interferons promoting cellular immunity [16, 17]. The multiple receptors of poly I:C 
make it an attractive option for addition to a multicomponent vaccine delivery system. 
TLR3 recognition in the endosome during liposome deformation, as well as RIG-I and 
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MDA-5 recognition in the cytosol after LLO-mediated cytosolic delivery may provide an 
enhanced or possibly synergistic adjuvant effect. 
 In addition, future immunization studies with glycolipid containing liposomes 
should investigate immune responses from CD4+ T cells. The immunization studies 
presented focused heavily on the induction of CD8+ T cell responses. However, CD4+ T 
cells play an important role in directing and promoting cell-mediated immunity. The 
ELISPOT assay and CD4+ tetramer staining could be implemented after immunizations 
to assess CD4+ T cell responses. Moreover, IL-12 and IL-5 ELISA experiments would 
give indications of the cytokine environment developed from vaccination. The presence 
of cytokines such as IL-12 and IFN-γ are critical for maintaining cellular immune 
responses, while IL-5 indicates Th2 immune responses (promoted by CD4+ Th2 cells) 
that stimulates humoral immunity [18].  
 The analysis of these glycolipid-containing liposomes as vaccines carriers may 
also benefit from more functional assays to describe the effectiveness of vaccination. 
The ELISPOT assay can be used as a functional assay, however, there are a few 
drawbacks. For example, ELISPOT assays to quantify CD8+ IFN-γ producing cells may 
provide misleading results since certain non-cytotoxic cells can secrete IFN-γ whereas 
CD8+ cytotoxic T lymphocytes (CTLs) with proven lytic activity do not always secrete 
IFN-γ. Moreover, there is a poor correlation between the IFN-γ ELISPOT assay and 
clinically relevant immune responses in humans [19]. An in vivo CTL assay would be 
additionally beneficial for analyzing the quality of the CTL response. 
 Further investigations may also assess the role of the Class B scavenger 
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receptors, CD36 and SR-BI in the recognition and uptake of PI-liposomes and GM1-
liposomes. CD36 and SR-BI have been previously described in the uptake of anionic 
liposomes containing PS or PI lipids [20, 21]. The interaction(s) of these receptors with 
GM1 lipid or GM1-liposomes to our knowledge has not been described. Uptake 
experiments similar to those described in Chapter 2, with PI- or GM1- fluorescent 
liposome formulations, could be performed after pre-incubation of macrophage and 
dendritic cell types with anti-SR-BI or anti-CD36. Importantly, these studies should be 
performed in macrophage and DC types from different sources (e.g. cell lines, primary 
cells, ex vivo naïve cells) as expression of the scavenger receptors may differ based on 
the cell source/type. The results from these studies would indicate if CD36 and/or SR-BI 
scavenger receptors are involved in the recognition of PI or GM1 lipids and the cell-
mediated endocytosis of liposomes. Since class B scavenger receptors can influence 
cell signaling pathways and additionally are involved in innate immunity that leads to 
pro-inflammatory responses [22-24], the results of such cell pathways after liposome 
treatment/uptake could also be analyzed to describe the impact of PI-liposome and 
GM1-liposome uptake on cell function and signaling. 
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APPENDIX A 
Competition Uptake Studies with Glycolipid-Containing Liposome Formulations 
 
SUMMARY 
 The glycolipid liposome formulations previously studied were analyzed for their 
uptake after cells had been pre-treated to non-fluorescent (competing) liposomes. 
These studies were performed to distinguish which liposome formulations may compete 
for binding and uptake sites on cells. Liposomes containing 10mol% phosphatidylserine 
(PS) (PS-liposomes; PS-lip) negatively affected subsequent uptake of liposomes 
containing 10mol% phosphatidylinositol (PI) (PI-liposomes; PI-lip) in both JAWSII 
dendritic cells and J774 macrophages, but had no effect of the uptake of liposomes 
containing 10mol% monosialotetrahexosylganglioside (GM1) (GM1-liposomes; GM1-
lip). A separate observation was pre-treatment of cells with PI-lip negatively affected 
subsequent uptake of PI-lip in JAWSII dendritic cells (DCs), but this was not the case in 
J774 macrophage cells. PI-lip uptake was not affected by pre-treatment of cells with 
GM1-lip. Furthermore, GM1-lip uptake was unaffected by pre-treatment with GM1-lip or 
PI-lip. These results indicate that PS-lip and PI-lip compete for binding sites in JAWSII 
DCs and J774 macrophage cells. PI-lip and GM1-lip appear to have different recognition 
sites on JAWSII DCs and J774 macrophages.   
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INTRODUCTION 
Endocytosis is a means of cell uptake that takes the forms of phagocytosis, 
receptor-mediated endocytosis and pinocytosis. Antigen presenting cells (APCs), such 
as macrophages and dendritic cells (DCs), are proficient in endocytosis. Two primary 
functions of APCs are to endocytose material and then present it to T cells as part of the 
immune response or tolerance. Macrophages are particularly adept at internalizing 
many forms of materials including soluble proteins, whole cells, and liposomes [1, 2]. 
DCs are less active than macrophages in endocytosis and are more tailored for the 
antigen presentation role. However, DCs are considered to be highly active in 
pinocytosis [3, 4]. The ability of DCs to capture material is also dependent on the cells 
state of maturity. Immature dendritic cells (iDCs) are highly efficient at endocytosis while 
mature DCs (mDCs) down regulate this activity [5, 6].  
The primary uptake mechanism of liposomes is endocytosis [7]. More 
specifically, the liposomes in the presented studies are presumed to undergo receptor-
mediated endocytosis [7, 8]. The uptake of PI-liposomes, GM1-liposomes and PS-
liposomes are dramatically different in vitro and in different cell types, which would 
presumably be a result of receptor-mediated uptake by recognition of specific lipid head 
groups, rather than a non-specific method of uptake [8]. 
As previously discussed, PI-liposome show distinct uptake behavior in 
macrophages and DCs. Where the presence of only 10mol% PI lipid in a liposome 
composition can promote liposomal uptake by JAWSII DCs, J774 macrophages 
required 50mol% PI to reach comparably high uptake levels of PI-liposomes. The 
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increased recognition and uptake of PI-liposomes by JAWSII DCs was hypothesized to 
be a result of some cell-surface receptor or other binding site that recognized PI lipid. 
The Class B scavenger receptors SR-BI and CD36 have been indicated in the uptake of 
anionic lipids such as PI and PS [9, 10], however there is no dedicated PI, PS, or GM1 
receptor that has been described to date. 
 
MATERIALS AND METHODS 
Liposome preparation 
Cholesterol (Chol) was obtained from Calbiochem (La Jolla, California). All non-
fluorescent lipids were obtained from Avanti Polar Lipids (Alabaster, Alabama). Oregon 
Green® 488 1,2-Dihexadecanoyl-sn-Glycero-3 Phosphoethanolamine (Oregon 
Green 488-DHPE) was obtained through Life Technologies  (Grand Island, New York). 
Liposomes were prepared at a 2:1 molar ratio of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (Δ9-cis)  (DOPC) to Chol. In uptake experiments, Oregon Green 488-
DHPE lipid was incorporated at 1mol% of the total phospholipid. L-α-
phosphatidylinositol (Soy) (PI), monosialotetrahexosylganglioside (ovine brain) (GM1), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000] (PEG-PE) or L-α-phosphatidylserine (porcine brain) (PS) were incorporated at 
indicated mol% of the total phospholipid. Lipid mixtures were dried into a lipid film using 
a Buchi Rotavapor R-200 rotary evaporator. Lipids were dried completely then 
rehydrated with isotonic (290 ± 10 mmol/kg osmolality) HEPES-buffered saline 
containing EDTA (HBSE) (10mM HEPES, 140mM NaCl, 1mM EDTA, pH 7.4). Hydrated 
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lipid films were vortexed, subjected to 5 freeze/thaw cycles and extruded using double-
stacked polycarbonate 100 nm diameter filters (GE). The size of the liposomes and zeta 
potential was determined using a Malvern ZS90 ZEN 3600 zetasizer. Phospholipid 
content of liposomes was quantified using Bartlett’s phosphate assay [11]. Determined 
phospholipid concentrations signified the concentration of liposomes and were used in 
the dosing calculations. GM1 does not have a phosphate group and thus the 
phospholipid assay concentrations determined do not include GM1 content of the 
liposomes; dosing calculations were adjusted to account for this. Prepared liposome 
samples were stored at 4°C and used within 10 days of preparation 
 
Cell culture 
All tissue culture media and reagents were purchased from Invitrogen (Carlsbad, 
CA) unless otherwise noted. All cells were maintained in in a humidified incubator at 
37°C and 5% CO2. J774A.1 mouse macrophages (ATCC TIB-67) and JAWSII mouse 
dendritic cells (ATCC CRL-11904) were purchased from ATCC (Manassas, Virginia).  
J774 cells were maintained in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% heat-inactivated FBS (HI-FBS) and 100μg/mL streptomycin, 
100U/mL penicillin. JAWSII cells were maintained in alpha minimum essential medium 
with ribonucleosides and deoxyribonucleosides supplemented with 20% HI-FBS, 100 
μg/mL streptomycin, 100U/mL penicillin, 2mM L-glutamine and 5ng/ml murine GM-CSF 
(PeproTech, Inc. Rocky Hill, New Jersey).  
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In vitro cell uptake  
 Equal counts of cells suspended in serum-free DMEM were aliquoted into 
Eppendorf tubes. Increasing concentrations of the non-fluorescent, competing 
liposomes (100μM, 250μM, 500μM, or 1mM [phospholipid]) were incubated with cell 
samples for 30 minutes at 4°C, unless otherwise noted. After treatment, any non-cell 
bound liposomes were removed by centrifugation and three subsequent cell washes in 
serum-free DMEM. Next, OregonGreen488 fluorescently labeled liposomes were added 
(100μM final [phospholipid]) to cell samples suspended in serum-free DMEM for 1 hour 
at 37°C. After treatment any non-cell bound liposomes were removed by centrifugation 
and three subsequent cell washes in phosphate buffered saline (PBS) pH 7.4. Cell 
fluorescence was obtained using a BD FACSCalibur flow cytometer (San Jose, CA). 
Cell Quest software was used to plot fluorescence values and obtain the mean 
fluorescence intensity (MFI) of samples.  
 
RESULTS AND DISCUSSION 
To further characterize the uptake of the glycolipid-containing liposome 
formulations a series of competition experiments were performed. Cells were pre-
treated with a liposome formulation (competitor) for a short amount of time before being 
exposed to secondary fluorescently labeled liposome formulation whose uptake was of 
interest. During pre-treatment, in the case that liposomes bind to a cell-surface site or 
receptor, those cell-bound liposomes would then be endocytosed by the cell. This would 
leave less of these binding sites or receptors on the cell surface, which would affect the 
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uptake of subsequent liposomes added to the cell sample if the two liposome 
formulations examined were to share these sites for uptake (i.e., competition). We also 
studied the impact of pre-treatment concentrations on subsequent cell liposomal uptake 
of fluorescent liposomes. The highest competition ratio studied was 10:1; with 10 times 
more non-fluorescent liposomes pre-incubated with cells than subsequent fluorescent 
liposome concentration incubated with the cells.  
We first investigated the possibility of PS-lip and PI-lip being recognized by the 
same cell-surface receptor or cell-surface component. Cell samples were pre-treated 
with non-fluorescent PS-liposomes before being washed and treated with fluorescent 
PI-liposomes. In the presence of increasing concentrations of PS-liposomes, PI-
liposomes showed reduced uptake by JAWSII DCs and J774 macrophage cells (Figure 
A.1A). This suggests that PS-lip was binding some cell-surface site(s) on macrophages 
and DCs, which also facilitates uptake of PI-lip. When the same competition experiment 
was performed with non-fluorescent PS-lip and fluorescent GM1-lip there were no 
obvious negative effects on GM1-uptake. This was observed in both J774 macrophages 
and JAWSII DCs. Previously, even at 100μM PS-lip treatment concentration, JAWSII 
DCs and J774 macrophages exhibited similarly high uptake of PS-lip; therefore the 
increased concentrations used in this competition experiment (500μM or 1mM) most 
likely resulted in the internalization of a large amount of binding sites and cell membrane 
due to PS-lip uptake. The observation that PS-lip pre-treatment of cells did not affect the 
uptake of GM1-lip in the same cells suggests these liposome formulations do not 
compete for cell-surface binding sites (Figure A.1B).  
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In a separate set of similar competition experiments, we identified that GM1-lip 
and PI-lip did not negatively affect the uptake of one another mediated by either JAWSII 
DCs or J774 macrophage cells (Figure A.2A and A.2B). The uptake of interest was 
unaffected even when a high, 1mM concentration, of competing liposome was pre-
incubated with cells. This result indicates that PI-lip and GM1-lip bind different cell-
surface binding sites for uptake or are recognized and internalized by different cell-
surface receptors. 
In continuing with the competition studies, PI-liposomes were observed to 
compete with each other for uptake by JAWSII DCs but not by J774 macrophage cells 
(Figure A.3A). The same result was observed whether pre-treatment was carried out at 
4°C (permits liposome binding only) or at 37°C (permits liposome internalization) (37°C 
pre-treatment condition data not shown). The decreased DC uptake of fluorescent PI-
liposomes of interest could to be a result of previously described high DC uptake of PI-
liposomes. The increased binding of PI-lip during pre-treatment likely diminished the 
binding sites available on DCs for following PI-liposomes. This is presumably not a 
problem for PI-lip uptake by J774 cells. However, this cannot be explained by low 
uptake of PI-lip during pre-treatment, because while PI-lip does enhance DC uptake of 
liposomes, the overall uptake of PI-lip is similar between macrophages and DCs due to 
macrophages’ enhanced capacity for uptake. The concept of quicker receptor ‘recycling’ 
to the surface of macrophages for enhanced fluorescent PI-lip uptake is also not a 
viable explanation since pre-treatment was performed at 4°C, a temperature at which 
only liposome binding occurs. An increased amount of binding sites for PI-lip on 
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macrophages may explain this result observed in J774 macrophages. This explanation 
seems to directly conflict previous in vitro uptake results, which indicate PI-lip do not 
promote liposomal uptake by macrophages. However, it is possible that macrophages 
possess more binding sites, albeit with less specificity for PI-lip. 
GM1-liposomes do not compete with each other for uptake in either cell type 
(Figure A.3B). This result was also observed when pre-treatment was carried out at 4°C 
or 37°C (37°C pre-treatment condition data not shown). It is interesting that GM1-
liposome pre-treatment presented no observable effect on uptake of liposomes in any of 
the competition experiments performed (Figure A.2A and A.3B). This may be a result of 
the inherent long-circulating property of GM1-lip in both DC and macrophages cell 
types. GM1-containing liposomes exhibit consistent, low uptake over a large dose range 
in vivo [12]. The increasing concentrations of GM1-lip introduced in these studies may 
have had little change in the amount of liposomes that were internalized by cells, 
therefore presenting no challenge to the secondary liposome formulation’s uptake.  
 
CONCLUSION 
 JAWSII DCs and J774 macrophages appear to have different sites of recognition 
for PI-liposomes and GM1-liposomes. The uptake of the glycolipid formulations was not 
affected by competition with one another. PI-lip does compete with PS-lip for uptake in 
JAWSII DCs and J774 macrophages cells. PS-lip uptake may diminish binding sites on 
cells that are necessary for PI-lip uptake. Interestingly, GM1-lip uptake was unaffected 
by pre-treatment of cells with PS-lip, PI-lip or GM1-lip, even at the highest competition 
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ratios examined. Generally low GM1-lip uptake by cells may allow GM1-lip uptake to be 
unaltered even if there are less binding sites present on cells following liposome pre-
treatment. Since PI-liposomes seemingly compete with each other for uptake by JAWSII 
DCs but not in J774 macrophage cells, there appears to be a more specific recognition 
and uptake mechanism for PI-lip on DCs.  
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Figure A.1 PI-lip compete with PS-lip for uptake by macrophages and DCs 
Cells were pre-treated for 30 min at 4°C with the non-fluorescent competing liposome 
formulation (PS-liposomes) at increasing concentrations from 100 μM (1:1 competition) 
to 1 mM (10:1 competition). Cells were washed to remove non-associated PS-
liposomes. Then fluorescently labeled liposomes of interest were incubated with cells for 
1 hour at 37°C. The liposome uptake of interest was monitored by OregonGreen488-
DHPE fluorescence of cell samples. The x-axis represents fluorescence of cells (A) 
Competition of PS-liposomes with (A) PI-liposomes or (B) GM1-liposomes in J774 
macrophages and JAWSII DCs. 
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Figure A.2 PI-lip and GM1-lip do not compete for binding sites on macrophages 
and DCs 
Cells were pre-treated for 30 min at 4°C with the non-fluorescent competing liposome 
formulation at increasing concentrations from 100 μM (1:1 competition) to 1 mM (10:1 
competition). Cells were washed to remove non-associated liposomes. Then 
fluorescently labeled liposomes of interest were incubated with cells for 1 hour at 37°C. 
The liposome uptake of interest was monitored by OregonGreen488-DHPE 
fluorescence of cell samples. The x-axis represents fluorescence of cells (A) GM1-lip 
(pre-treatment) and fluorescent PI-lip uptake (B) PI-lip (pre-treatment) and fluorescent 
GM1-lip uptake in J774 macrophages and JAWSII DCs. 
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Figure A.3 Pre-treatment of JAWSII DCs with PI-lip inhibits subsequent uptake of 
PI-lip 
Cells were pre-treated for 30 min at 4°C with the non-fluorescent competing liposome 
formulation at increasing concentrations from 100 μM (1:1 competition) to 1 mM (10:1 
competition). Cells were washed to remove non-associated liposomes. Then 
fluorescently labeled liposomes of interest were incubated with cells for 1 hour at 37°C. 
The liposome uptake of interest was monitored by OregonGreen488-DHPE 
fluorescence of cell samples. The x-axis represents fluorescence of cells (A) PI-lip (pre-
treatment) and fluorescent PI-lip uptake (B) GM1-lip (pre-treatment) and fluorescent 
GM1-lip uptake in J774 macrophages and JAWSII DCs. Pre-treatment was also 
performed at 37°C to permit liposome internalization and the results were in agreement 
with those shown. 
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APPENDIX B 
Characteristics of Glycolipid-Containing Liposomes 
 
SUMMARY 
 The glycolipid-containing liposomes presented in this thesis are easily prepared 
and have reproducible liposome characteristics. These are two important factors that 
potentiate the further development of these liposome formulations as vaccine delivery 
carriers. Liposomes were sized down by either sonication or extrusion methods, both of 
which produced liposomes of a suitable size (<200nm) for subcutaneous injection and 
local lymph node targeting of liposomes. Furthermore, liposome preparations had poly 
dispersity index (PDI) values in the ideal range (<0.3) for nanoparticle formulations. PDI 
is a measurement of the width of size distribution, which indicates the heterogeneity of 
nanoparticle formulations. In order to make accurate calculations of encapsulated 
material and the amount of liposomes needed to provide a therapeutic effect, PDI must 
be low and reproducible from batch-to-batch. Independent preparations of liposomes 
consistently had similar zeta potential values, indicating glycolipid composition was 
comparable. Liposomes had low encapsulation efficiency of ovalbumin (OVA), with 
typically 2-3% encapsulated. Methods could be improved upon to (1) decrease liposome 
loss during extrusions, and (2) increase encapsulation of OVA in liposomes. 
Incorporation of phosphatidylinositol (PI) glycolipid in DOPC liposomes has been shown
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in this thesis to promote dendritic cell uptake of liposomes and produce CD8+ T cell-
mediated immune responses, indicating them as beneficial vaccine delivery systems. 
Further benefit of using PI lipid is it’s plentiful sourcing from plants (soy), as opposed to 
monosialotetrahexosylganglioside (GM1) glycolipid sourcing from brain tissues. 
Nevertheless, either PI- or GM1-containing liposomes are simple to prepare and 
possess reproducible liposome characteristics, which is necessary for cost-effective 
vaccine development. 
 
INTRODUCTION 
 Size and surface charge are important physicochemical factors that can be easily 
and quickly measured to predict liposome uptake behaviors. Dynamic light scattering 
(DLS) determines size of liposomes and provides a measure of size range, known as 
the poly dispersity index (PDI). The size of nanoparticles is one of the most important 
factors for liposome delivery to peripheral tissues and uptake by certain cells [1-5]. The 
charge surrounding a particle, known as zeta potential, is another parameter than can 
drastically affect liposome uptake as well as stability. Anionic particles have zeta 
potentials below -10mV, while particles with zeta potentials in the range of -10mV to 
+10mV are considered approximately neutral [6]. Negatively charged lipids, such as 
phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidyglycerol (PG) added 
to a liposome formulation can increase stability of liposomes in solution [7-9], however 
these lipids’ negative charge also enhances liposome uptake by cells [10-12]. Sterically-
stabilized or long-circulating liposomes utilize phosphatidylinositol (PI), 
	 144	
monosialotetrahexosylganglioside (GM1), or poly(ethylene) glycol (PEG)-conjugated 
lipids to increase stability of liposomes in vitro and in vivo [13-16]. Although these lipids 
are also negatively charged, their bulky hydrophilic head groups contribute to stability 
and deters rapid uptake of these liposomes by macrophages [2, 11, 17].   
Other important characteristics of liposomes include phosphate concentration, 
indicating lipid recovery from preparation, and the concentration of encapsulated 
materials in liposomes. These factors are of critical importance in development of 
nanoparticles for vaccine delivery, as extensive loss of liposome and/or antigen(s) 
would likely increase costs of production. 
 
MATERIALS AND METHODS 
Liposome preparation 
Cholesterol (Chol) was obtained from Calbiochem (La Jolla, California). All lipids 
were obtained from Avanti Polar Lipids (Alabaster, Alabama). Liposomes were prepared 
at a 2:1 molar ratio of 1,2-dioleoyl-sn-glycero-3-phosphocholine (Δ9-cis) (DOPC) to 
Chol. L-α-phosphatidylinositol (Soy) (PI) and monosialotetrahexosylganglioside (ovine 
brain) (GM1) were incorporated at 10 mol% of the total phospholipid. pH-sensitive 
liposomes contained L-α-phosphatidylethanolamine (egg, chicken) (ePE) and 
cholesteryl hemisuccinate (CHEMS) (Sigma-Aldrich) at a 2:1 molar ratio. Lipid mixtures 
were dried into a lipid film using a Buchi Rotavapor R-200 rotary evaporator. Lipids were 
dried completely then rehydrated with isotonic (290 ± 10 mmol/kg osmolality) HEPES-
buffered saline containing EDTA (HBSE) (10mM HEPES, 140mM NaCl, 1mM EDTA, pH 
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7.4). Alternatively, liposomes to be used for immunization studies had lipid films 
rehydrated with isotonic (290 ± 10 mmol/kg osmolality) HBSE, pH 8.4 containing soluble 
ovalbumin (OVA) (Grade VI, Sigma-Aldrich) at 25 mg/ml and LLO at 250 μg/ml. 
Hydrated lipid films were vortexed and subjected to 5 freeze/thaw cycles. Liposomes 
prepared by extrusion (empty liposomes) were extruded 4 times using double-stacked 
polycarbonate 100 nm diameter filters (GE). Liposomes prepared by sonication 
(liposomes containing OVA/LLO) were subject to 8x1min cycles of sonication using a 
water bath sonicator. Size exclusion chromatography using a 1x25cm Sepharose CL-4B 
column (GE Healthcare) was used to remove unencapsulated protein in liposome 
formulations prepared with protein in the lipid film hydration solution. Prepared liposome 
samples were stored under argon gas at 4°C. Liposomes were used within 10 days of 
preparation. 
 
Liposome characterization 
The size of the liposomes and zeta potential was determined using a Malvern 
ZS90 ZEN 3600 zetasizer. Liposomes were diluted in HBSE buffer, pH 7.4 for the sizing 
and zeta potential measurements. Phospholipid content of liposomes was quantified 
using Bartlett’s phosphate assay [18]. Absorbance was read on a Molecular Dynamics 
Emax plate reader at 805 nm. Phospholipid concentrations of liposome samples were 
determined based on a standard curve of known phosphate concentration(s) generated 
for each assay. Determined phospholipid concentrations signified the concentration of 
liposomes, which were used in the dosing calculations. GM1 does not have a phosphate 
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group and thus the phospholipid assay concentrations determined do not include GM1 
content of the liposomes; dosing calculations were adjusted to account for this. 
Quantification of encapsulated protein was determined using SDS-PAGE. Proteins were 
resolved on a 4-20% Tris-glycine gel (Invitrogen) with 1X electrode buffer (250mM 
Trizma, 2M glycine) containing 0.1% SDS. Gels were stained with Krypton protein stain 
(Pierce) and protein band intensities were measured on a Typhoon 9200 (Molecular 
Dynamics). Protein content was quantified using ImageQuant (GE Healthcare) based on 
known protein content run on the same gel. Measured total encapsulated protein 
amount was divided by total protein amount added to liposomes in the hydration 
solution, x100 to obtain encapsulation efficiency (%). 
 
Lipid calculations 
  The surface area of a sphere, 4πr2 was used to measure the outer liposomal 
surface area. The outer surface area of the liposome was divided by the relative surface 
area (nm2) of lipid head group(s) for the indicated lipid composition at specified mole 
ratios, providing the total number of lipids estimated to be in the outer leaflet of the lipid 
bilayer. The head group surface areas of lipids used are as follows: DOPC: 0.62 nm2 
[19]; PI: 0.7 nm2; GM1: 1.0 nm2 [20-22]. The PI lipid head group surface area was 
estimated based on the surface area of phosphatidylglycerol (PG) head group=0.66 nm2 
[19]. 
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RESULTS AND DISCUSSION  
The liposome formulations outlined in Table B.2 are the main liposome 
formulations studied in vitro and in vivo in this thesis. The average diameter(s) of 
liposomes prepared by extrusion through 100nm polycarbonate filters was ~120nm with 
less than 10% deviation in diameter between differing formulations and between 
individual preparations of identical liposome formulations. The heterogeneity of the 
sample, indicated by the poly dispersity index (PDI) was more variable, but remained 
lower than 0.3, which is ideal for nanoparticle formulations. PDI values can range from 0 
to 1, where values less to 0.05 are rarely seen other than with highly monodisperse 
samples, and a value above 0.7 indicates a highly broad size distribution. Preparation of 
liposomes by sonication is preferred when encapsulating listeriolysin-O (LLO). Previous 
work with LLO-containing liposomes has proven extrusion of these liposome 
formulations to be problematic (unpublished data). In these experiments we used bath 
sonication, as to avoid a probe-type sonicator that may shed material into the sample 
during sonication. Alike extrusion, sonication of liposomes produces liposomes of a 
smaller diameter. However, sonication of liposome preparations is more time-
consuming, does not size the liposomes used in the studies below ~150nm diameter 
and results in a higher PDI value (Table B.2). Nevertheless, the liposomes formulations 
prepared by sonication were similar in size and PDI, and these values were 
reproducible in batch-to-batch liposome preparations. Although these liposomes are 
larger than those prepared by extrusion, their size (<200nm) is sufficient to drain into the 
lymphatic system after subcutaneous injection [1, 23]. 
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The measured zeta potential of PI- and GM1- liposomes was typically between    
-9mV and -11mV. This suggests these glycolipid-containing liposomes are only very 
slightly anionic, as a zeta potential between -10mV and +10mV is approximately neutral 
[6]. PI-liposomes had slightly lower zeta potential which is likely a result of the charge 
shielding effect previously described of PI- and GM1-containing liposomes [14]. The 
bulky carbohydrate groups of these glycolipids in the liposome formulation have been 
theorized to shield the negative charge present in the glycolipid head groups. From the 
zeta potential measurements in Table B.2, it appears the bulkier GM1 lipid head group 
may better shield the negative charge located in its head group, resulting in a less 
negative zeta potential compared to PI-containing liposomes. The ability of GM1 to 
better shield negative charge would also explain why GM1-liposomes are more capable 
of deterring rapid macrophage uptake in vitro and in vivo compared to PI-liposomes.  
The phospholipid concentration determined by Bartlett’s assay was another 
reproducible feature of these liposome formulations (Table B.3). This assay specifically 
measures the concentration of phosphate (in phospholipids). Lipid mixtures contained 
10μmol of total lipid (DOPC, PI, GM1) hydrated in 500μL HBSE buffer, resulting in a 
20mM phosphate concentration before extrusion. The exception to this is GM1, which 
does not contain a phosphate group. Since GM1 is not reactive in the phosphate assay 
and therefore is not monitored, the phosphate concentration of GM1-containing 
liposomes is lower than liposome formulations such as DOPC:Chol or DOPC:Chol:PI, 
which contain only phospholipids (Table B.3).  Liposomes that contain only DOPC:Chol 
have 10μmol  DOPC added, whereas the glycolipid-containing liposomes 
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(DOPC:Chol:PI or DOPC:Chol:GM1) contain 9μmol  DOPC and 1μmol  of either PI or 
GM1. This 1μmol glycolipid content of the total 10μmol lipid content is why glycolipid-
containing liposomes are labeled as 10mol% PI-liposomes or 10mol% GM1-liposomes. 
The 10mol% GM1 in the liposomes that is not monitored in the phosphate assay is 
confirmed in the liposome formulation in zeta potential measurements, which show a 
more negative surface charge compared to the neutral DOPC:Chol liposomes and a 
similar zeta potential to 10mol% PI-containing liposomes (Table B.2). After extrusion, 
liposomes are much less concentrated than 20mM indicating some liposomes are lost in 
the extrusion process. The addition of glycolipid to DOPC:Chol liposome formulation 
does not negatively impact the liposome recovery from extrusion. Liposomes that were 
formulated encapsulating material (e.g. LLO and OVA) were passed through a 
Sepharose CL-4B column to remove unencapsulated protein, which largely affects 
phosphate concentration. Liposome [phosphate] concentration is substantially diluted in 
the column flow-through buffer. Concentrated liposome samples collected from the 
column had a typical final phosphate concentration ranging from 2 nmol/μl to 5 nmol/μl 
(mM). The volume of concentrated samples was typically ~1-2ml. More dilute liposome 
samples could also be collected from the column (<2nmol/μl; ~1ml). 
The outer surface appearance (i.e. outer lipid membrane leaflet components) of 
the liposomes is important for cell recognition. As established in Chapter 2 and in 
Appendix A, the presence of different lipids in the liposome formulation can have drastic 
effects on liposome uptake by cells. Table B.4 summarizes the appearance of the outer 
liposome membrane leaflet in terms of total lipid number and total glycolipid number. 
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The outer surface area of liposomes prepared by extrusion is approximately 4.522x10-14 
nm2 for the 120nm diameter liposome. Liposomes of 120nm diameter and composed of 
DOPC, Chol, and PI had approximately 72,006 lipids in the outer membrane leaflet, of 
which 7,200 are PI glycolipid. There are a slightly smaller number of lipids, 68,723, 
when the larger GM1 head group is incorporated in the DOPC, Chol bilayer of 
liposomes. Thus, GM1-containing liposomes contain approximately 6,872 glycolipids in 
the outer membrane leaflet, a less than 5% difference in number of glycolipids 
compared to PI-containing liposomes. Liposomes that were prepared by sonication and 
used in the immunization studies presented in Chapter 3 are slightly larger in area with 
an outer surface area of 1.075x10-13 nm2 (based on avg. diameter of 185nm). In these 
larger liposomes, the total number of lipids in the outer liposome membrane leaflet in 
the DOPC:PI liposome is 169,826 and in DOPC:GM1 liposomes, 163,373. The total 
number of glycolipids would be 16,982 in DOPC:PI liposomes and 16,337 in 
DOPC:GM1 liposomes, more than twice that estimated to be in the outer membrane 
leaflet of 120nm diameter liposomes. The difference in glycolipid number becomes 
smaller as size of liposomes increases, where in 185nm diameter liposomes the 
difference is less than 4%. 
Both PI and GM1 lipids extend perpendicularly from the lipid bilayer into the 
aqueous space [24, 25]. The hydration of these large hydrophilic lipid head groups 
results in a large bulky surface area. For PI-containing liposomes this can result in 
defects in the packing of PC lipids in the liposome bilayer, resulting in increased water 
penetration in the liposome [25]. A less tightly packed lipid bilayer when PI is 
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incorporated would suggest there are less lipids in a PI-containing liposome of the same 
size as a liposome containing only DOPC, for example [25]. Alternatively, GM1 in the 
lipid membrane can increase the packing of different lipids resulting in less aqueous 
leakage from liposomes [26-28]. These differences in bilayer packing are not only a 
result of the glycolipid head group, but also of the lipid hydrocarbon chain length and 
saturation, which are summarized in Table B.1. PI from soy has a mixed unsaturated 
(16:0) and saturated (18:2) fatty acid composition that could contribute to less tightly 
packed lipid bilayers. The carbon double bonds are found in the middle of the 
hydrocarbon chain, which form kinks in this carbon tail region, resulting in less van der 
Waals interactions with other lipid’s hydrocarbon tails in the bilayer. GM1 consists of 
18:0 and 18:1 fatty acid components, and the one carbon double bond is located near 
the lipid head group, allowing for its longer hydrocarbon tails to have increased van der 
Waals interactions with other lipids in the bilayer. The increased chain length and van 
der Waals interactions with GM1 can form more stable and rigid bilayers.  
GM1 has been found asymmetrically distributed in lipid bilayers because of its 
large hydrated head group [29]. Although, in that study, liposomes had an average of 
only 20nm diameter, the small size of which likely affected the ability of bulky GM1 head 
groups (1.2nm length [24]) to distribute in the inner membrane leaflet. Nonetheless, 
steric hindrance and high hydration caused by the GM1 head group may still play a role 
in the distribution of GM1 in the liposome membrane. So while the mol% of glycolipids 
was matched in GM1- or PI-liposome formulations studied here, there may be slightly 
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more GM1 glycolipid located on the outer membrane leaflet, increasing the predicted 
glycolipid value given in Table B.4. 
As these liposome formulations investigated in this thesis have the potential to be 
used as vaccine carriers, it was imperative to determine how much antigen and other 
components are encapsulated in liposome preparations. A drawback to using liposomes 
in any delivery context is that they have typically low encapsulation of materials. Lipid 
films were hydrated with 25mg/ml OVA but prepared liposome formulations contained 
approximately 0.2mg/ml OVA (Table B.5). The determined encapsulation efficiency was 
~3% for OVA. The protein LLO was encapsulated at a much higher efficiency than OVA, 
with typically ≥50% of total LLO added encapsulated. The lack of encapsulation of OVA 
may be remedied in a few ways. More OVA may become encapsulated if lipid films are 
simply hydrated with less volume, thereby allowing more of the added volume to be 
encapsulated in liposomes. Another approach to increase OVA concentration inside the 
liposomes may be to increase the freeze/thaw cycles during liposome preparation [30]. 
Alternatively, the reverse-phase evaporation method for preparing liposomes may 
increase encapsulation efficiency of hydrophilic molecules [31]. Changing lipid features 
such as hydrocarbon length and degree of saturation can also affect encapsulation of 
material in liposomes [32]; however, changing lipid content is also likely to have effects 
on stability, uptake of liposomes, as well as the liposomal delivery of material inside 
cells. The glycolipid incorporated in the liposome composition did not significantly affect 
ratios of OVA to LLO encapsulated in the liposomes; there was typically ~3-5X more μg 
OVA than μg LLO encapsulated in either glycolipid-containing liposome formulation. 
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This ratio was additionally similar to the OVA:LLO ratio when pH-sensitive ePE:CHEMS 
liposome composition was compared.  
The bulky carbohydrate head groups and negative charge of PI- and GM1-
glycolipid-containg liposomes are speculated to contribute to decreased fusion and 
aggregation of liposomes in solution [17, 33-35]. DLS measurements support this, 
showing one single narrow peak indicative of one vesicle size population with a narrow 
size range (Figure B.1) Furthermore, uptake studies as described in Chapter 2 
generated similar results when liposomes were prepared up to 10 days prior. So while 
the impact of storage on liposomes was not directly monitored, reproducible results 
could be obtained with liposome up to 10 days post-preparation, suggesting liposomes 
are stable for a short time as prepared. Liposome aggregates or liposomes that had 
fused would likely have different uptake characteristics [14, 36]. However, assays to 
monitor aggregation as well as leakage of glycolipid-containing liposomes over time 
would add significant value in the characterization of these liposomes delivery vehicles.    
 
CONCLUSION 
 The characteristics of these glycolipid-containing liposome formulations 
presented are highly reproducible batch-to-batch. They are similar in terms of size, zeta 
potential, phosphate concentration and liposomal surface glycolipid content. Liposome 
preparation by sonication methods could be improved upon to provide higher 
encapsulation of OVA. Overall, glycolipid-containing liposomes are of easy preparation 
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with reproducible characteristics, adding further value to their future potential as 
liposomal vaccine carriers. 
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Table B.1 Lipid characteristics 
*   Synthetic phospholipids are prepared from glycerophosphocholine (GPC) derived 
from plant or animal sources. The typical plant source of GPC is soybean lecithin. 
u Predominant fatty acid species in lipid product 
Information provided by Avanti Polar Lipids, lipid manufacturer, expect where noted 
 
 
 
 
  
Lipid name Acronym 
Lipid 
source Purity 
Carbon chain 
length:double 
bonds; fatty acid 
name(s)u 
Molecular 
Weight 
(g/mol) 
Charge at 
pH 7 
1,2-dioleoyl-sn-glycero-3-
phosphocholine (Δ9-cis) DOPC Synthetic* >99% 18:1; oleic acid 786.113 Neutral 
L-α-
phosphatidylethanolanime ePE 
Chicken, 
egg >99% 
18:1; oleic acid 
18:0; stearic acid 748.608 Neutral 
L-α-phosphatidylinositol PI Soy >99% 
18:2; linoleic acid 
16:0; palmitic acid 866.647 Negative 
L-α-phosphatidylserine PS 
Porcine, 
brain >99% 
18:1; oleic acid 
18:0; stearic acid 824.966 Negative 
Monosialotetrahexosyl-
ganglioside GM1 
Ovine, 
brain >99% 
18:0; stearic acid  
18:1; sphingosine 1568.805 Negative 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
[methoxy(polyethylene 
glycol)-2000] 
PEG-PE; 
PEG-
DSPE Synthetic* >99% 18:0; stearic acid  2805.497 Negative[37] 
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Liposome 
composition Size* (nm) (SD) 
Poly dispersity 
index (PDI )(SD) 
Zeta potential 
(mV) (SD) 
Preparation by extrusion  
DOPC:Chol:PI 
(10mol% PI-lip) 115.54 (9.87) 0.086 (0.079) -11.29 (0.87) 
DOPC:Chol:GM1 
(10mol% GM1-lip) 118.32 (10.53) 0.078 (0.044) -8.29 (0.64) 
 
DOPC:Chol 123.06 (8.38) 0.119 (0.058) -5.56 (0.49) 
Preparation by sonication  
 
DOPC:PI 196.83 (27.75) 0.275 (0.025) -10.24 (0.79) 
 
DOPC:GM1 186.74 (25.19) 0.280 (0.064) -9.20 (0.68) 
 
ePE:CHEMS 173.73 (6.36) 0.214 (0.028) -23.94 (1.94) 	
Table B.2 Liposome size, poly dispersity index and zeta potential  
The particle size and poly dispersity index (PDI) of liposomes were determined after 
liposome preparation by extrusion or sonication. Size (diameter; nm) was determined by 
dynamic light scattering at 22°C. PDI is a dimensionless measure of the width of particle 
size distribution. Zeta potential measured in HBSE, pH 7.4 at 22°C Zeta potential was 
determined by electrophoresis and laser Doppler velocimetry. All measurements were 
performed by a Malvern Zetasizer ZS90. Data shown is representative of 8 separate 
preparations of liposomes by extrusion, or 3 separate preparations of liposomes by 
sonication.  
SD: standard deviation 
*Size listed is Z-average particle size 
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Liposome composition Phosphate concentration (mM) (SD) 
DOPC:Chol:PI 
(10mol% PI-lip) 13.02 (3.36) 
DOPC:Chol:GM1 
(10mol% GM1-lip) 11.03 (2.19) 
 
DOPC:Chol 14.51 (2.34) 	
Table B.3 Phosphate content of liposome preparations 
Phosphate content of liposomes was quantified using Bartlett’s phosphate assay. 
Absorbance was read at 805nm. Data shown is representative of 10 separate 
preparations of liposomes by extrusion. SD: standard deviation 					 	
	 158	
	
Liposome 
composition 
Mole 
ratio 
# of outer 
surface 
lipids 
Outer surface area 
(nm2) of liposome 
# of outer 
surface 
glycolipid  
Preparation by extrusion 
DOPC:Chol:PI 
(10mol% PI-lip) 9:5:1 72,006 4.522x10-14 7,200 
DOPC:Chol:GM1 
(10mol% GM1-lip) 9:5:1 68,723 4.522x10-14 6,872 
 
DOPC:Chol 2:1 72,935 4.522x10-14 NA 
Preparation by sonication 
 
DOPC:PI 9:1 169,826 1.075x10-13 16,982 
 
DOPC:GM1 9:1 163,373 1.075x10-13 16,337 
 
ePE:CHEMS 2:1 173,387 1.075x10-13 NA 	
Table B.4 Features of liposomal surface  
Lipid head group areas are as follows: DOPC: 0.62 nm2; PI: 0.7 nm2: GM1: 1.0 nm2. 
The total number of outer surface lipids and total number of outer surface glycolipid 
were calculated based on a relative lipid head group size for the indicated lipid 
composition at specified mole ratios. Liposomes prepared by extrusion had an average 
120nm diameter. Liposomes prepared by extrusion had an average 185nm diameter. 
NA: not applicable 
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Liposome 
composition 
Liposomal OVA 
concentration (μg/μl) 
(SD)  
Liposomal LLO 
concentration (μg/μl) 
(SD) 
OVA:LLO 
ratio 
 
DOPC:PI 0.162 (0.059) 0.041 (0.010) 4.0 
 
DOPC:GM1 0.228 (0.059) 0.046 (0.001) 5.0 
 
ePE:CHEMS 0.202 (0.063) 0.035 (0.004) 5.8 
 
 
Table B.5 OVA and LLO encapsulation in liposomes 
Liposome preparations used for immunizations were analyzed for their liposomal OVA 
and LLO content. The concentration of OVA and LLO shown is the mean and standard 
deviation (SD) for two separate liposomes preparations. OVA:LLO ratios were 
calculated based on total μg of OVA and LLO determined in liposome samples. The 
ratio shown is an averaged ratio from 6 liposome samples in 2 independent liposomes 
preparations. 
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(A) 
 
(B) 
 
 
Figure B.1 Representative DLS size measurement plots 
Representative dynamic light scattering (DLS) size measurement plots from liposomes 
prepared by extrusion through double-stacked 100nm polycarbonate filters (A) or 
sonication 8x1min cycles (B). 
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